US20210030819A1 - Edible plant parts enriched with probiotic bacteria - Google Patents
Edible plant parts enriched with probiotic bacteria Download PDFInfo
- Publication number
- US20210030819A1 US20210030819A1 US17/046,103 US201917046103A US2021030819A1 US 20210030819 A1 US20210030819 A1 US 20210030819A1 US 201917046103 A US201917046103 A US 201917046103A US 2021030819 A1 US2021030819 A1 US 2021030819A1
- Authority
- US
- United States
- Prior art keywords
- bacteria
- plant
- edible
- probiotic bacteria
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 313
- 239000006041 probiotic Substances 0.000 title claims abstract description 257
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 256
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 249
- 235000018927 edible plant Nutrition 0.000 title claims abstract description 126
- 238000000034 method Methods 0.000 claims abstract description 55
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 39
- 241000196324 Embryophyta Species 0.000 claims description 173
- 210000001519 tissue Anatomy 0.000 claims description 137
- 241000894007 species Species 0.000 claims description 77
- 230000001580 bacterial effect Effects 0.000 claims description 56
- 230000012010 growth Effects 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 21
- 230000009286 beneficial effect Effects 0.000 claims description 20
- 239000002702 enteric coating Substances 0.000 claims description 19
- 238000009505 enteric coating Methods 0.000 claims description 19
- 239000013543 active substance Substances 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 17
- 230000002496 gastric effect Effects 0.000 claims description 16
- 235000013406 prebiotics Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 241000736262 Microbiota Species 0.000 claims description 7
- 230000003111 delayed effect Effects 0.000 claims description 7
- 210000001723 extracellular space Anatomy 0.000 claims description 7
- 210000003093 intracellular space Anatomy 0.000 claims description 7
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 230000001332 colony forming effect Effects 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 230000001902 propagating effect Effects 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 241000194033 Enterococcus Species 0.000 claims description 4
- 230000003190 augmentative effect Effects 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000192132 Leuconostoc Species 0.000 claims description 3
- 241000192001 Pediococcus Species 0.000 claims description 3
- 230000003416 augmentation Effects 0.000 claims description 3
- 230000000644 propagated effect Effects 0.000 claims description 3
- 244000005700 microbiome Species 0.000 abstract description 14
- 241000194032 Enterococcus faecalis Species 0.000 description 27
- 235000003228 Lactuca sativa Nutrition 0.000 description 22
- 241000186605 Lactobacillus paracasei Species 0.000 description 21
- 241000208822 Lactuca Species 0.000 description 21
- 239000002609 medium Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 235000013305 food Nutrition 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 210000000936 intestine Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 229920001817 Agar Polymers 0.000 description 11
- 235000014469 Bacillus subtilis Nutrition 0.000 description 11
- 239000008272 agar Substances 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 241000282849 Ruminantia Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 230000037213 diet Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940032049 enterococcus faecalis Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 244000005709 gut microbiome Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 238000000527 sonication Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 241000186869 Lactobacillus salivarius Species 0.000 description 6
- 240000008415 Lactuca sativa Species 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000003319 supportive effect Effects 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000008199 coating composition Substances 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 4
- -1 ny Species 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 208000027244 Dysbiosis Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 230000007140 dysbiosis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 244000005702 human microbiome Species 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid group Chemical group C(C=1C(C(=O)O)=CC=CC1)(=O)O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 3
- 230000008635 plant growth Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000425347 Phyla <beetle> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000009337 Spinacia oleracea Nutrition 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960005069 calcium Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000004280 healthy diet Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000013029 homogenous suspension Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229960003284 iron Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 210000004215 spore Anatomy 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 240000006740 Cichorium endivia Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000366676 Justicia pectoralis Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241001293495 Lactuca virosa Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000136948 Ocimum sanctum Species 0.000 description 1
- 235000004072 Ocimum sanctum Nutrition 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000036579 abiotic stress Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000000183 arugula Nutrition 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000012681 biocontrol agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000003733 chicria Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000021582 food-grade substance Nutrition 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000003621 irrigation water Substances 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002351 pectolytic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 230000008659 phytopathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Definitions
- the present invention relates to edible plant tissue enriched with probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome.
- the present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue.
- the human microbiota is the microbial community best described as “the sum of all microbial life living in or on the human body (Fricke, W. F. et al. J. Pediatr. 165, 8-10, 2014). It is an entity that has wide-reaching metabolic, nutritional, and immunological effects on the host, and as such has generated an interest within the biomedical research community.
- the microbiome evolves within a healthy host from birth to death, maintaining a homeostatic balance with the host's immune system. Healthy adult humans each typically harbor more than 1000 species of bacteria belonging to a relatively few known bacterial phyla with Bacteroidetes and Firmicutes being the dominant phyla (Catherine A. et al., Nature 489, 220-230, 2012).
- the microbiota of the gut is quite diverse compared to other body sites, and there is considerable variation in the constituents of the gut microbiota among apparently healthy individuals (Human Microbiome Project Consortium. Nature 486, 207-14, 2012). Recently, the Human Microbiome Project (HMP) reported a profound insight into the role of the microbiota in human health. For example, gut microbes train the immune system, protect against opportunistic pathogens, harvest nutrients and energy from diet, and ferment non-digestible carbohydrates. The disruption of the normal gut microbiota (dysbiosis) is associated with obesity, diabetes, various inflammatory bowel diseases (IBD) and autoimmune diseases. Many factors, either endogenous or exogenous, affect the composition of the gut microbiota. Endogenous factors include the host genotype, age, sex and both the adaptive and innate immune system. Exogenous factors include diet, exposure to medications and toxins, and illness, while diet exerts the largest impact on the gut microbiota.
- Endogenous factors include the
- Probiotics are live microorganisms, that, when administered in adequate amounts, confer a health benefit on the host (Backhed, F. et al. Cell Host Microbe 12, 611-622, 2012).
- probiotics have been studied as a means to modulate microbial populations and functions in order to promote health and prevent or manage intestinal disorders (Ringel, Y. et al., Am. J. Gastroenterol. Suppl. 1, 34-40, 2012). Accumulated data from clinical trials indicate that certain intestinal disease conditions associated with intestinal dysbiosis, e.g.
- Plants are a basic and substantial part of human daily diet. Vegetables, fruit, herbs, nuts, and medicinal herbs belong to the raw-eaten plant parts. Human food thus comprises all parts of plants including associated microorganisms that can be colonized by up to 10 4 -10 10 microorganisms per gram of plant. These microbial populations inhabit different habitats throughout the plant organs including the phyllosphere (lettuce, cabbage), the rhizosphere (carrots, turnip), the carposphere (tomato, banana), as well as the seeds (beans, peas) and corresponding endospheres (Berg, G. et al., in: Principles of Plant-Microbe Interactions 419-426, Springer International Publishing, 2015. doi:10.1007/978-3-319-08575-3_44).
- Endophytes are plant-endosymbiotic group of microorganisms, often bacteria or fungi. Endophytic bacteria colonize the internal tissues of plants showing no external sign of infection or negative effect on their host.
- the population of endophytes in a plant species is highly variable and depends on various components including, e.g., host species, host developmental stage, inoculum density and environmental condition.
- Obligate endophytes are being transmitted from the host plant to its seed; however, facultative endophytes spend only part of their life cycle in the inner tissue of plants. These endophytes enter the plant through different points including tissue wounds, stomata (pores found in the epidermis of leaves), lenticels (raised pores in the stems of woody plants), root cracks, and germinating radicals (the part of the embryo that develops into the root system). In addition, active penetration may be enabled by the secretion of pectolytic enzymes. Next, the endophytes inhabit the plant tissue either intercellular or through the vascular tubes.
- endophytes seem to be ubiquitous in plant tissues, having been isolated from various parts of plants like flowers, fruits, leaves, stem, root, and seeds in various plant species (Indira Devi, S. and Momota, P. in Plant Microbes Symbiosis: Applied Facets 147-162, Springer India, 2015. doi:10.1007/978-81-322-2068-8_7).
- Bacillus pumilus isolated from tissues of the medicinal plant Ocimum sanctum exhibited probiotic properties such as acid tolerance, bile salt tolerance, auto-aggregation, antibiotic resistance and the absence of haemolytic activity (Murugappan R M et al., Symbiosis 60, 91-99, 2013, DOI 10.1007/s13199-013-0244-0).
- the present invention provides a platform technology for producing a superior delivery vehicle of probiotic bacteria conferring a beneficial health effect on a host animal subject.
- the delivery vehicle is plant-based, combining highly efficient delivery of the beneficial probiotic bacteria to their site of action with the nutritional and health-promoting components of plant produce, particularly fresh plant produce.
- the technology of the present invention is based in part on the unexpected discovery that bacteria known to have probiotic effect on animal subjects can be habituated to colonize plant tissues in significant amounts and in viable form.
- the probiotic bacteria are habituated by selection and direct evolution and/or enrichment processes.
- the present invention thus provides an edible plant part or tissue enriched with probiotic bacteria colonized therein and its use for oral delivery of the bacteria.
- the edible plant part colonized with probiotic bacteria of the present invention is advantageous over hitherto known microbiotic delivery vehicles as, in addition to protecting the bacteria from non-favorable environmental conditions, the edible plant part by itself has high nutritional values.
- Edible plant tissues are rich in non-digestible or low-digestible food ingredients that benefit the animal host (prebiotics), dietary fibers, and micro- and macro-nutrients.
- prebiotics animal host
- dietary fibers dietary fibers
- micro- and macro-nutrients micro- and macro-nutrients.
- the combination of probiotic bacteria and prebiotic characteristics of the edible plant tissue results in a synergic effect that selectively stimulates the growth of the probiotic bacterial community and promotes its activity in gastrointestinal tract of non-ruminant animals, specifically humans.
- the edible plant part is used as a fresh produce.
- the plant tissues provide the probiotic bacteria with suitable conditions for colonization, such that the probiotic bacteria are kept in a viable, preferably propagating form, such that high quantity of high-quality probiotic bacteria is delivered to the subject.
- the probiotic bacteria are capable of affecting the structure and/or function of the recipient gastrointestinal bacterial population that is at least maintained healthy or improved to a healthier state.
- the plant tissue further provides protection to the probiotic bacteria from harsh environmental conditions and thus prolonging the shelf life of the bacteria.
- the edible plant part may be further coated with agents providing for a delayed release of the probiotic bacteria, particularly enteric coating agent(s) protecting the colonized probiotic bacteria from the acidic pH of the stomach.
- the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- GI gastrointestinal
- the edible plant part or tissue derived therefrom comprises at least 10 4 colony forming units (CFU) of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- CFU colony forming units
- At least 80% by weight of the edible plant part or tissue derived therefrom comprises at least 10 5 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- At least 80% by weight of the edible plant part or tissue derived therefrom comprises at least 10 6 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- the at least one probiotic bacteria species comprises at least 15% of the total bacteria species colonizing the edible plant part or tissue derived therefrom.
- the probiotic bacteria are present at a site selected from the group consisting of the edible plant part or tissue intercellular space the edible plant part or tissue intracellular space, and a combination thereof. According to certain embodiments, the probiotic bacteria are further present on the edible plant part or tissue surface. According to certain exemplary embodiments, the probiotic bacteria are colonized within the intercellular and intracellular space. According to additional exemplary embodiments, the probiotic bacteria are present in the intercellular space, the intracellular space and the surface of the edible plant part or tissue.
- the at least one probiotic bacteria species is a non-endophytic species, not previously demonstrated to colonize plant tissues.
- the at least one probiotic bacteria species is an endophytic species capable of naturally colonizing a plant.
- the concentration of the enriched probiotic bacteria in the edible plant part or tissue is higher compared to the concentration of the same probiotic bacteria in a corresponding edible plant part of a control plant.
- the control plant is a plant to which the probiotic bacteria were not intentionally applied at any growth stage.
- the control plant may harbor naturally occurring probiotic bacteria without the intervention according to the present invention.
- probiotic bacterial species capable of surviving and/or proliferating in and/or on a plant tissue after been intentionally applied directly or indirectly is encompassed within the teachings of the present invention.
- the CFU of the at least one probiotic bacterial cell can be in an active state or in a dormant state.
- the CFU of the at least one probiotic bacterial species is an active bacterial cell. According to other embodiments, the CFU is in a dormant state selected from the group consisting of a spore, a cyst and a resting-cells. According to other exemplary embodiments, the CFU of the at least one probiotic bacterial species is in a dormant form of a spore.
- the present invention provides a plurality of edible plant parts or tissues derived therefrom, wherein at least 80% of the plurality of edible plant parts is enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- GI gastrointestinal
- the edible plant part enriched with probiotic bacteria is as described hereinabove.
- the edible plant part is selected from the group consisting of leaf, fruit, root, tuber, bulb, stem, seed and any combination thereof.
- the edible plant part comprises prebiotic components.
- the prebiotic components include dietary soluble and/or insoluble fibers, including, for example, fructo-oligosaccharide.
- the fructo-oligosaccharides are selected from the group consisting of, but not limited to, inulin, lactulose, and resistant starch.
- the edible plant part comprises at least one of ⁇ -carotene, ascorbic acid, riboflavin, folic acid, iron, calcium, manganese, phosphorous, zinc and any combination thereof.
- the edible plant part is low in calories.
- the edible plant part is a plant fresh produce harvested from the plant.
- the tissue is a fresh tissue derived from a freshly harvested edible plant part.
- the edible plant part or tissue derived therefrom is dried. Any method as is known in the art to dry the edible plant part without negatively affecting the viability of the probiotic bacteria colonized therein can be used according to teachings of the present invention.
- the edible plant part or the tissue derived therefrom are not fermented.
- the edible plant part is a leafy produce of the plant, including, but not limited to, lettuce, spinach, endive, chard and arugula.
- the probiotic bacteria are gram positive bacteria. According to certain embodiments, the probiotic bacteria are gram negative bacteria. According to some embodiments, the probiotic bacteria are of a genus selected from the group consisting of Enterococcus, Bifidobacterium, Lactobacillus, Propionobacterium, Bacillus, Streptococcus, Pediococcus, Escherichia, Leuconostoc , and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- the probiotic bacteria are of a species selected from the group consisting of Enterococcus faecalis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus rhamnosus, Lactobacillus casei B, Bacillus subtilis and any combination thereof.
- Enterococcus faecalis Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus rhamnosus, Lactobacillus casei B, Bacillus subtilis and any combination thereof.
- Enterococcus faecalis Bifidobacterium lactis, Bifidobacterium bifidum
- Lactobacillus acidophilus Lactobacill
- the probiotic bacteria are of a species selected from the group consisting of Enterococcus faecalis, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus salivarius , and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- the edible plant part enriched with the colonized probiotic bacteria or the tissue derived therefrom is coated with a suitable agent and or formulation providing for a delayed release of the bacteria.
- the coating comprises enteric coating protecting the plant tissues from the acidic pH of the stomach. Once the entering coating is dissolved in the intestine, the edible plant tissues are amenable to digestion by microbiota already present in the intestine and the delivered probiotic bacteria are released.
- the edible plant part or tissue derived therefrom is coated with enteric coating when the probiotic bacteria are beneficially active in the intestine.
- the present invention discloses for the first time that an edible plant part or a tissue derived therefrom coated with enteric coating can be used for oral delivery of a biologically active ingredient present therein, wherein the active ingredient reaches the intestine in its active form.
- the enteric coating prevents digestion of the edible plant tissue within the stomach, and thus prevents exposure of the biologically active ingredient to the acidic, harmful pH of the stomach.
- the entering coating is dissolved, exposing the plant tissue to digestion and release of the active ingredient stored therein.
- the present invention provides an edible plant part or a tissue derived therefrom comprising at least one biologically active agent, coated with enteric coating.
- the biologically active agent is probiotic bacteria.
- the coated edible plant part or tissue derived therefrom further comprises at least one additional active agent selected from the group consisting of a nutritionally active agent, a therapeutically active agent and a combination thereof.
- the additional active agent is a by-product of the presence of the probiotic bacteria.
- the enteric coating comprises Cellulose Acetate Phthalate (CAP).
- CAP Cellulose Acetate Phthalate
- the present invention provides a method for oral delivery of probiotic bacteria to a subject in need thereof, the method comprising orally administering to the subject an effective amount of an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of said subject.
- GI gastrointestinal
- the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of said subject for use in a method for oral delivering to a subject an effective amount of the probiotic bacteria.
- GI gastrointestinal
- the edible plant part or tissue enriched with the probiotic bacteria are as described hereinabove.
- the edible plant part or tissue derived therefrom enriched with at least one colonized probiotic bacterial species is coated with enteric coating.
- the probiotic bacteria reach the subject intestine. According to some embodiments, the probiotic bacteria propagate in the subject intestine.
- the method results in altering the subject gastrointestinal microbiota profile compared to the profile before administering to said subject the edible plant part or tissue derived therefrom enriched with the at least one probiotic bacterial species.
- the method results in a beneficial therapeutic effect.
- the therapeutic effect comprises treating or preventing GI-related disease or disorder.
- An initial bacteria load of 10 7 CFU/g is recommended for probiotic food, for example, yogurt.
- the high numbers have been suggested to compensate for the possible loss in the numbers of the probiotic bacteria during passage through the stomach and intestine.
- a higher bacteria load of 10 10 CFU/g of yogurt is used to ensure delivery of a greater number of live probiotic bacteria to the target sites, e.g. small intestines and colon.
- the plant-based delivery vehicle of the present invention may enable several magnitude lower load of the probiotic bacteria, as the plant tissue provide the bacteria both with protection through the GI passage and initial energy source at the site of activity, enabling immediate proliferation of the probiotic bacteria at the site of action.
- the method results in a beneficial cosmetic effect.
- the cosmetic effect comprises regulation of skin appearance.
- skin appearance regulation includes, but is not limited to, reduction of skin acne, reduction of skin flaking and reduction of signs of skin aging. Each possibility represents a separate embodiment of the present invention.
- the subject is a non-ruminant mammal. According to certain exemplary embodiments, the subject is human.
- the edible plant part, tissue derived therefrom, the probiotic bacteria and the entering coating are as described hereinabove.
- the present invention provides a method for selecting and/or producing probiotic bacterial species having endophytic characteristics of being capable of growing in a plant tissue, the method comprising:
- the method is repeated at least once as to confirm the capability of the selected probiotic bacteria to colonize in a plant.
- the method of the present invention for selecting probiotic bacterial species capable of colonizing plant tissues encompasses isolating bacteria from augmented leaf a week after inoculation and/or from newly developed plant tissues that are not directly inoculated with the probiotic bacteria. Thus, only bacteria that can survive, propagate and spread within the plant tissue are selected, optimizing the selection of probiotic bacteria to be used according to the teachings of the present invention.
- the selected probiotic bacteria capable of colonizing a plant tissue can be identical to the bacteria strain initially applied to the plant or part thereof, or can exhibit modified characteristics and thus be identified as modified strain or even as a new strain of bacteria, with the proviso that the modified or new strain exhibit probiotic characteristics.
- the present invention provides a method for producing an edible plant part enriched with at least one probiotic bacteria species capable of inhabiting the gastrointestinal (GI) tract of an animal, the method comprising:
- the method further comprises the steps of:
- steps (i)-(iii) are repeated at least once.
- the plant part is selected from the group consisting of seeds, stems and leaves. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the plant part is a seed.
- the at least one probiotic bacterial species is suspended in a liquid.
- the liquid is water.
- the liquid is a culture medium.
- the liquid is applied to the plant or part thereof by a method selected from the group consisting of infiltration, immersion/dipping, incubation, spraying, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- the plant part is a seed.
- the at least one probiotic bacterial species is applied to the seed via seed coating.
- a plurality of seeds is coated with a seed coating agent comprising the at least probiotic bacterial species.
- a plurality of plants is grown from the plurality of seeds.
- FIG. 1 shows partitioning of the introduced bacteria to epiphytes and endophytes in leaves of plantlets developed from seeds coated with carboximetilculose (CMC)-probiotic bacteria mixture, when separation is performed by sonication.
- CMC carboximetilculose
- ATCC American Type Culture Collection
- EF E. Faecalis
- LP L. Paracasei
- BS B. subtilis
- Gut probiotics are live microbes that beneficially affect an animal host by modulating mucosal and systemic immunity, as well as improving intestinal function and microbial balance in the gastrointestinal tract.
- Various nutritional and therapeutic effects have been ascribed to probiotics including: modulating immune response, lowering serum cholesterol concentrations, improving lactose intolerance symptoms, increasing resistance to infectious intestinal diseases, decreasing duration of diarrhea, reducing blood pressure, and helping to prevent colon cancer.
- probiotics In order to exert their beneficial effects on the host, probiotics must remain viable and reach the intestine in large numbers.
- the present invention provides a platform technology providing plant material that is a vehicle for orally delivering beneficial probiotic bacterial species to the gastrointestinal tract, and particularly to the intestine of a non-ruminant animal subject in need thereof.
- the plant material is typically fresh produce which by itself provides healthy food ingredients including dietary fibers, vitamins, micro- and macronutrients.
- the plant part is leafy fresh produce, which is also low in calories.
- the plant material comprises prebiotic ingredients that induce the growth or activity of the probiotic bacteria once reaching the subject gastrointestinal tract.
- All plants are inhabited internally by diverse microbial communities comprising bacterial, archaeal, fungal, and protistic taxa. Bacteria are associated with plants in various ways, part of which leading to plant diseases and damage to the plant life, but part having beneficial effects on the plant growth and characteristics. Endophytic bacteria are generally defined as bacteria colonizing plants without causing visible harm. Endophytic bacteria benefits from their host plant, receiving a constant food supply and being sheltered from environmental stress. In exchange, bacterial endophytes may offer several benefits to the host plant, particularly growth promotion in terms of increased germination rates, biomass, leaf area, chlorophyll content, nitrogen and protein content, hydraulic activity, yield and tolerance to abiotic stresses. Some endophytes protect their host plant from pathogens and can act as biocontrol agents.
- endophyte and “endophytic” with reference to bacteria refers to bacteria capable of colonizing plants without causing visible harm to the plant.
- Endophytic bacteria can be obligate endophytes, i.e. bacteria that live within plant tissues for the entirety of its life cycle or facultative (transient), i.e. bacteria which may spend only part of the life cycle within the plant.
- probiotic bacteria capable of inhabiting the gastrointestinal (GI) tract of an animal
- GI gastrointestinal
- probiotic bacteria have therapeutic beneficial effect in preventing and/or treating a disease or disorder.
- probiotic bacteria have a nutritional beneficial effect.
- the probiotic bacteria improve the general well-being of the subject consuming same.
- prebiotic is directed to compounds (for example, dietary compounds in food) that can induce or aid with the growth or activity of probiotic microorganism.
- a prebiotic is a substrate that is selectively used by a microorganism, or selectively affect the microorganism.
- the prebiotic is an edible plant tissue or a compound derived therefrom.
- the terms “exogenously applied” and “intentionally applied” refer to the application of isolated gut probiotic bacteria of at least one species, or of an agricultural composition comprising same. It is to be explicitly understood that the probiotic bacteria to be applied are enriched with the desired isolate species or plurality of species. Accordingly, application of agricultural compositions contaminated with probiotic bacteria (for example manure used for fertilization, manure-contaminated irrigation water) is referred to herein as unintentional application and is specifically excluded from the teachings of the present invention.
- colony forming unit and CFU (in single or plural) are used herein interchangeably as an indicative number of viable bacteria.
- a compound or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- GI gastrointestinal
- the edible plant part or tissue may be enriched with one genus and/or species and/or strain of probiotic bacteria or with a combination thereof.
- the probiotic bacteria are gut bacteria, i.e. bacteria found in the gut microbiome of a non-ruminant animal.
- the plant part or tissue may be enriched with various species or strains present at equal amounts or at different amounts, at equal or different proportions.
- the present invention is based in part on the application of isolated probiotic bacteria enriched for selected species or plurality of species to a plant or a part thereof which results in the enrichment of an edible part of the plant with the probiotic bacteria species or plurality of species.
- the at least one probiotic bacteria species comprise at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23% at least 24% at least 25% at least 26% at least 27% at least 28% at least 29% at least 30% or more of the total bacteria species colonizing the edible plant part or tissue derived therefrom.
- the edible plant part or tissue derived therefrom comprises at least 10 4 colony forming units (CFU) of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- CFU colony forming units
- the edible plant part or tissue derived therefrom comprises from about 10 4 CFU/g plant tissue to about 10 11 CFU/g plant tissue or any subranges thereof.
- the amount of probiotic bacteria can range from about 10 4 CFU/g to about 5 ⁇ 10 10 CFU/g, or from about 10 4 CFU/g to about 10 9 CFU/g, or from about 10 6 CFU/g to about 5 ⁇ 10 9 CFU/g.
- the amount of probiotic bacteria ranges from about 10 4 CFU/g plant tissue to about 10 8 CFU/g plant tissue.
- At least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% by weight of the edible plant part or tissue derived therefrom comprises at least 10 5 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- At least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% by weight of the edible plant part or tissue derived therefrom comprises at least 10 6 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- the terms “colony forming unit” and “CFU” are used herein interchangeably in its broadest meaning in the art.
- the CFU of the at least one probiotic bacterial species is a bacterial cell in an active state.
- the CFU of the at least one probiotic bacterial species is in a dormant state selected from the group consisting of a bacterial spore, a bacterial cyst and a bacterial resting-cell.
- the at least one probiotic bacteria species has not been previously demonstrated to colonize plant tissues, and thus are define as non-endophytic bacteria.
- the probiotic bacteria are of endophytic bacteria species capable of naturally colonizing a plant.
- the concentration of the enriched probiotic bacteria in the edible plant part or tissue is higher compared to the concentration of the same probiotic bacteria in a corresponding edible plant part of a control plant.
- the control plant is a plant to which the probiotic bacteria were not intentionally applied at any growth stage.
- the control plant may harbor naturally occurring probiotic bacteria without the intervention according to the present invention, but at a lower amount and/or at a different species composition and/or at a different species proportions.
- the present invention provides methods for selecting and/or producing probiotic bacterial species capable of colonizing in plants.
- the present invention further provides methods for enriching an edible plant part or tissue with the probiotic bacteria that acquired the capability to grow and proliferate within plant tissues.
- probiotics as functional food components should demonstrate diverse properties. Importantly, no adverse effects may be associated with the presence of the bacterial species in the animal body.
- the majority of bacteria belonging to the Lactobacillus and Bifidobacterium genera are recognized as safe and beneficial as probiotics. Lactobacillus and Bifidobacterium genera are normal residents of the microbiota in the human gastrointestinal tract, in which they develop soon after birth. It is generally accepted that, with the only exception of streptococci and enterococci, lactic acid bacteria are rarely pathogenic to humans and animals. Specific strains of Enterococcus, E. faecium and E.
- probiotic bacteria positively affect the human health through a wide variety of different putative mechanisms. They involve the reinforcement of the intestinal barrier, alterations of the immune response, and development of antagonism to pathogens either by the production of antimicrobial compounds or throughout competitive activities towards mucosal binding sites (Ouwehand, A. C. et al., Int. Dairy J. 9, 43-52, 1999).
- Any bacterial species and/or strain known to have a beneficial probiotic activity when present in the gastrointestinal tract of a non-ruminant mammal, particularly human subject can be used according to the teachings of the present invention.
- the probiotic bacteria are gram positive bacteria. According to certain embodiments, the probiotic bacteria are gram negative bacteria. Several genera of bacteria are known to have probiotic activity (Fijan S. International journal of environmental research and public health 11(5), 4745-4767, 2014). According to some embodiments, the probiotic bacteria are of a mammal not pathogenic genus selected from the group consisting of Enterococcus, Bifidobacterium, Lactobacillus, Propionobacterium, Bacillus, Streptococcus, Pediococcus Escherichia, Leuconostoc , and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- the probiotic bacteria are of the species Enterococcus faecalis.
- the probiotic bacteria are of the species, Lactobacillus paracasei.
- the probiotic bacteria comprises a combination of Enterococcus faecalis and Lactobacillus paracasei .
- the method of the present invention for selecting and/or producing probiotic bacterial species capable of growing in a plant comprises the following steps:
- the plant part is selected from the group consisting of seeds and leaves.
- the method is repeated at least once as to confirm the capability of the selected probiotic bacteria to grow in a plant, specifically to colonize the intercellular and intracellular space of the plant tissues.
- the at least one probiotic bacterial species is suspended in a liquid.
- the liquid is applied to the plant or part thereof by a method selected from the group consisting of infiltration, immersion/dipping, incubation, spraying, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- the plant part is a seed.
- the at least one probiotic bacterial species is applied to the seed via seed coating.
- a plurality of seeds is coated with a seed coating formulation comprising the at least probiotic bacterial species.
- a plurality of plants is grown from the plurality of seeds.
- the seed coating formulation comprises at least one adherent selected from the group consisting of carboxymethyl cellulose, alginate, gums, starches, lecithins, formononetin, polyvinyl alcohol, alkali formononetinate, hesperetin, polyvinyl acetate, cephalins, Gum Arabic, Xanthan Gum, Mineral Oil, Polyethylene Glycol (PEG), Polyvinyl pyrrolidone (PVP), Arabino-galactan, Methyl Cellulose, PEG 400, Chitosan, Polyacrylamide, Polyacrylate, Polyacrylonitrile, Glycerol, Triethylene glycol, Vinyl Acetate, Gellan Gum, Polystyrene, Polyvinyl, Gum Ghatti, and polyoxyethylene-polyoxybutylene block copolymers.
- adherent selected from the group consisting of carboxymethyl cellulose, alginate, gums, starches, lecithins, formononetin, polyvin
- the method of the present invention for selecting probiotic bacteria encompasses selection of the bacteria from plant part(s) or tissues not necessarily directly inoculated. This type of selection is of high significance, as the selected bacteria can survive, propagate and spread within the plant tissues, indicating valid endophytic characteristics.
- the bacteria selected at step (e) may be identical to the bacteria applied to the plant or part thereof at step (a), or the selected bacteria may comprise genetic variation compared to the bacteria first applied. According to these embodiments, modified or new sub-strains may be produced.
- mice model system is used to validate the probiotic characteristics of the modified or new sub-strain.
- the present invention provides an edible plant part or a tissue derived therefrom enriched with at least one probiotic bacterial species selected or produced according to the method of the invention.
- the present invention provides a method for producing an edible plant part enriched with at least one probiotic bacteria species capable of inhabiting the gastrointestinal (GI) tract of an animal, the method comprising:
- the method further comprises the steps of:
- steps (i)-(iii) are repeated at least once.
- the present invention harnesses the phenomenon of endophytic bacteria to provide a superior vehicle for oral delivery of probiotic bacteria to non-ruminant animal, particularly to humans.
- the plant provides the probiotic endophytic bacteria with the environmental conditions required for the bacteria colonization and propagation.
- the colonized probiotic bacteria are delivered to the subjects within edible parts of the plant, typically fresh, such that there is no need to take any special measures to keep the probiotic bacteria alive until consumption.
- the plant tissues protect the probiotic bacteria, providing a sort of an encapsulation, such that significant number of viable probiotic bacteria reach their site of action. Accordingly, even relatively low number of the probiotic bacteria present in the edible plant part results in an effective number within the GI of the subject consuming same.
- plant fresh produce including fruit, vegetables, tubers, bulbs and leafy produce
- plant fresh produce are the most important raw-eaten food worldwide and are a substantial part of a balanced and healthy diet.
- Many beneficial effects on health and lifestyle are attributed to the consumption of fresh-cut or minimally processed edible plant products as they represent a good source of vitamins, e.g. ⁇ -carotene, ascorbic acid, riboflavin and folic acid as well as minerals, e.g. iron, calcium, manganese and phosphorous.
- plant fresh produce is known to be rich sources of micronutrients as well as dietary fiber, particularly in leafy produce, enabling the intake of these nutrients.
- the presence of non-digestible or low-digestible food ingredient characterizes plant fresh produce as prebiotic substance, stimulating the growth or activity of beneficial probiotic bacteria in the human colon (Biedrzycka B., Polish J. food Nutr. Sci. 13, 143-150, 2004).
- the probiotic bacteria are present at a site selected from the group consisting of the edible plant part or tissue intercellular space, the edible plant part or tissue intracellular space and a combination thereof.
- the prebiotic bacteria are further present on the edible plant part or tissues surface.
- the probiotic bacteria are colonized within the intercellular and/or intracellular space.
- the edible plant part comprises the at least one probiotic bacterial species actively growing. According to other embodiments, the edible plant part comprises the at least one probiotic bacterial species in its dormant form.
- the edible plant part is selected from the group consisting of leaf, stem, fruit, root, tuber, bulb, seed and any combination thereof.
- the edible plant part is rich in dietary fibers. According to certain additional or alternative embodiments, the edible plant part is rich in prebiotic components. According to certain additional or alternative embodiments, the edible plant part is rich in at least one of ⁇ -carotene, ascorbic acid, riboflavin, folic acid, iron, calcium, manganese, phosphorous, zinc and any combination thereof. According to certain additional or alternative embodiments, the edible plant part is low in calories.
- the edible plant part is a leafy produce of the plant.
- the probiotic bacteria are of a species selected from the group consisting of Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus salivarius, Enterococcus faecalis , and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- plant-derived edible vehicle of probiotic bacteria of the present invention provides protection to the probiotic bacteria from unfavorable environmental conditions and further at least partial protection to the bacteria through the transit via the stomach to the intestine.
- the present invention now discloses coating the edible plant part or tissue derived therefrom with a suitable coating to obtain a delayed release of the probiotic bacteria, so as to avoid exposure of the probiotic bacteria to the acidic pH of the stomach.
- delayed release refers to a time delay between oral administration of the edible plant part or tissue enriched with the probiotic bacteria and the release of said bacteria from the plant part or tissue. “Delayed release” may or may not involve gradual release of the probiotic bacteria over an extended period of time, and thus may or may not be “sustained release”.
- the coating is enteric coating.
- Enteric-coated formulations are suitable vehicles for modification of the release of drug or active agent at specific target areas within the gastrointestinal tract.
- Enteric coating is an effective method of protecting the drug or agent against a gastric environment and preventing its release before reaching the target site. Therefore, enteric polymer-coated formulations have been developed to prevent acid degradation in the stomach. In addition, the enteric coating must be readily soluble in alkaline buffer so that the drug or active agent is readily available for systemic absorption.
- Enteric polymers can be divided into three categories: (i) modified cellulosic derivatives e.g., cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate and (ii) methyl acrylate-methacrylic acid copolymers and (iii) other materials e.g., Shellac, polyvinyl acetate phthalate (Caillard, R. et al., Int. J. Pharm. 499, 321-329, 2016).
- modified cellulosic derivatives e.g., cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate and (ii) methyl acrylate-methacrylic acid copolymers and (iii) other materials e.g., Shellac, polyvinyl acetate phthalate (Caillard, R. et al., Int. J. Pharm. 499, 321-329,
- CAP Cellulose acetate phthalate
- CAP contains about 35% phthalyl and 24% acetyl groups (U.S. Pat. Nos. 4,960,814 and 5,025,004). It has been described that one carboxyl of the phthalic acid is combined with cellulose, and the other is free for further reactions. The resulting polymeric acid forms water-soluble alkaline salts.
- the present invention provides an edible plant part or a tissue derived therefrom comprising a biologically active agent, coated with enteric coating.
- the present invention encompasses coated edible plant parts or tissues comprising any biologically active agent that can habitat the edible plant part or be expressed therein.
- the biologically active ingredient is selected from the group consisting of a nutritionally active agent, a therapeutically active agent and a combination thereof.
- the biologically active agent is endogenous to the edible plant part. According to other embodiments, the biologically active agent is heterologous to the edible plant part.
- the biologically active agent is probiotic bacteria.
- the biologically active agent is selected from the group consisting of a protein, a polynucleotide, a vitamin, a chemotherapeutic agent, an anti-oxidant, an anti-aging agent.
- the present invention provides a food product comprising a plant tissue enriched with at least one probiotic bacterial species according to the teachings of the invention or a lysate thereof.
- the present invention provides an oral formulation comprising a plant tissue enriched with the at least one probiotic bacterial species according to the teachings of the invention or a lysate thereof.
- the plant tissue can be in a form selected from the group consisting of intact tissue, cut tissue, grinded tissue, and any combination thereof.
- the plant tissue is fresh, but may be present in other forms including frozen and dried form, as long as the probiotic bacteria preserve the ability to propagate once reaching a subject intestine.
- the oral formulation is a liquid formulation selected from the group consisting of suspensions, elixirs and solutions. According to certain embodiments, the oral formulation is a solid formulation selected from the group consisting of powders, tablets, capsules and pills.
- the plant tissue and the probiotic bacteria are as described hereinabove.
- the present invention provides a method for oral delivery of at least one species of gut probiotic bacteria to a subject in need thereof, the method comprising orally administering to the subject an effective amount of an edible plant part or a tissue derived therefrom enriched with the gut probiotic bacteria.
- the present invention provides an edible plant part or a tissue derived therefrom enriched with at least one gut probiotic bacteria species for use in oral delivery of an effective amount of the probiotic bacteria to a subject.
- the present invention provides use of an edible plant part or a tissue derived therefrom enriched with at least one gut probiotic bacteria species for oral delivery of the probiotic bacteria.
- the edible plant part or tissue derived therefrom enriched with at least one probiotic bacteria species is coated with enteric coating.
- the probiotic bacteria reach the intestine of a subject consuming the plant or part thereof. According to some embodiments, the probiotic bacteria propagate in the subject intestine.
- oral delivery of the edible plant part or tissue enriched with the probiotic bacteria results in altering the gastrointestinal microbiota profile of a subject consuming the edible plant part or tissue compared to the profile before consumption.
- oral delivery of the edible plant part or tissue provides a beneficial therapeutic effect to the subject.
- the therapeutic effect comprises comprising treating or preventing GI-related disease or disorder.
- Oral administration of the edible plant part or tissue enriched with probiotic bacteria may have a therapeutic effect in treating and/or preventing gastrointestinal tract related diseases or disorder, including, but not limited to diarrhea, diarrhea caused by antibiotic, arthritis, obesity, irritable bowel syndrome (IBS), cancer, heartburn, offset lactose intolerance; chronic fatigue syndrome and other forms of suffering from an unbalanced bacterial population in the intestine; in repopulation of the gut microbiome after antibiotic therapy; in inhibiting pathogenic bacteria; in supporting the immune system; in reducing cholesterol; in enhancing the bio-availability of calcium, zinc, iron, manganese, copper and phosphorus; and in synthesis of vitamins.
- a subject receiving and benefiting from such an oral administration include a non-ruminant mammal including human or a domestic animal or a farm animal such as cats, dogs, pigs, poultry or fish.
- oral delivery of the edible plant part or tissue provides a beneficial cosmetic effect to the subject.
- the present invention provides a cosmetic method comprising topically administering to a subject in need thereof a plant tissue enriched with at least one probiotic bacteria species or a lysate thereof.
- the lysate comprises a cosmetically effective amount of the probiotic bacteria.
- the lysate can be prepared by any method as is known in the art.
- the at least one probiotic bacterial species is as described hereinabove.
- the subject is a non-ruminant mammal.
- the subject is a human.
- probiotic bacteria species known to be capable of growing in the GI of an animal and have health beneficial effects were selected to be introduced into plant tissues.
- Enterococcus faecalis, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus salivarius, Streptococcus thermophiles and Bacillus subtilis belonging to different bacterial families, were purchased from ATTC and grown in culture in optimal conditions (Lactobacilli MRS agar (BD Difco), supporting growth of all lactobacilli; or Brain Heart Infusion (BHI, BD Difco) agar, general-purpose medium for the growth of a wide variety of bacteria, at 37° C.). Each bacteria species was collected from the agar plate and re-suspended in PBS to achieve a final concentration of 10 6 CFU/ml.
- CMC carboximetilcellularose
- Lettuce seeds were coated with the suspension of bacteria and CMC.
- the coated seeds were germinated in aseptic system of Hoagland No. 2 basal salt mixture agar (pH 6.5) and grown in a Plant Growing Room set to 22° C. and long day period of 12 hours of light.
- gut probiotic bacteria to plants via immersion of the bacteria in hydroponic media for plant growth requires that the gut probiotic bacteria can grow in the hydroponic medium, which typically includes fertilizers.
- Candidate probiotic bacteria or probiotic bacteria already shown to have the capability of endophytic growth are grown to form cell culture as described hereinabove.
- Plant hydroponic medium is inoculated with the bacteria culture and left to grow within the medium under conditions of hydroponic plant growth as are known in the art. Medium samples are taken at several time points (4 h, 24 h and 48 h) and the number of CFU/ml is counted. Probiotic bacteria propagating in the hydroponic medium are selected.
- Selected bacteria are grown to form a cell culture and added to the medium of hydroponically grown plants (e.g. lettuce). After about three and/or five days, leaf samples are taken, grinded in a buffer, and the number of CFU/leaf weight is measured as described hereinabove.
- the above-described protocols are suitable for selecting and/or enriching for probiotic bacteria with endophytic growth capabilities using other plants with edible leaves, for example spinach.
- the capability of the selected bacteria colonies to enter and grow in the plant is validated by isolating the bacteria from newly developed leaves to which the bacteria were migrated; growing the selected bacteria in sterile cultures; and applying the resulted culture to new plants according to the first method applied (leaf infiltration, seed coating, or immersion). The procedure is repeated for 2-10 rounds.
- the results of an exemplary experiment, in which the bacteria were first applied by seed coating, are presented in Table 3 hereinbelow.
- Probiotic bacteria that acquired endophytic characteristics i.e. being capable of surviving and multiplying in a plant tissue at significant concentrations selected as described hereinabove are defined as colonized bacteria having endophytic characteristics.
- the endophytic characteristics of the selected bacteria was examined by separating bacteria present onto the leaves (epiphytic bacteria) and bacteria present within the leaf tissue (endophytic bacteria).
- Lettuce seeds were coated with probiotic bacteria ( E. faecalis, L. Paracasei or B. subtilis ) and Carboxymethyl cellulose (CMC) solution as described hereinabove.
- the coated seeds were germinated in aseptic system. After 12 days, leaf samples of plants grown from the coated seeds were collected. Samples were sonicated in 900 ⁇ l sterilized saline in sonication bath (ultrasonic Elmasonic S 10/H; Frequency 50/60 H) for 7 min and then both saline (representing epiphytic bacteria) and crushed sonicated leaves (representing endophytic bacteria) were plated on supportive medium.
- probiotic bacteria E. faecalis, L. Paracasei or B. subtilis
- CMC Carboxymethyl cellulose
- colonized bacteria isolate of E. Faecalis, L. Paracasei , and B. subtilis were examined.
- the examined bacteria were isolated from lettuce leaves of plants after seven cycles of seed coating (with culture each of the bacteria species)—plant growth—isolation of bacteria from the plant leaves, confirming the endophytic growth characteristics of the bacteria.
- the isolated bacteria were grown in solutions simulating gastric fluid (SGF, containing 2 grams of NaCl; 3.2 g pepsin (Sigma; and 80 mL of 1 M HCl; mixed together to make 1 L with distilled water).
- SGF simulating gastric fluid
- the experiment was conducted as follows:
- CMC carboxymethyl cellulose
- E. Faecalis originated from cycle 10
- the coated seeds were germinated in aseptic system of Hoagland No. 2 basal salt mixture agar (pH 6.5).
- Leaves, originating from plants germinated from the coated seeds, were sampled 8, 13, 20 and 28 days after sowing (plantlets were immersed around day 4).
- the bacteria were extracted from each sample by crushing the leaves in Saline and plating it on supportive medium. Colonies that grew on the supportive medium were identified by sequencing of 16S rRNA gene. Data were subjected to one-way ANOVA, and pair-comparison of treatment means was achieved by Tukey's procedure at P ⁇ 0.05, using a statistical software (JMP). No significant difference in the bacteria amounts was observed during 28 days of growth ( FIG. 4 ).
- Enterococcus faecalis bacteria were collected from agar plate and blended with two different solutions: double distilled water (DDW) and 2% carboximetilculose (CMC). The final concentration of the E. faecalis bacteria was 10 6 CFU/ml. To form bacteria-CMC suspension, the solution was vigorously shaken until homogenous suspension was obtained
- Lettuce cut leaves were dipped in each of the two different bacterial solutions for 10 minutes.
- the coated leaves were kept in a sterile box in the refrigerator at 4° C.
- Example 7 Viability and Survival of Probiotic Bacteria in the GI of Mice Consuming Vegetative Tissues Enriched with the Probiotic Bacteria
- mice Male C57BL/6JOLAHSD mice 8 weeks old are fed for two consecutive days with three different diets:
- Control group (1) diet containing regular mice food (5 mice);
- Control group (2) diet containing regular mice food mixed with regular lettuce (5 mice);
- Test group diet containing regular mice food mixed with lettuce enriched with the probiotic bacteria Enterococcus faecalis according to the teachings of the present invention (5 mice).
- mice from control group 2 and the test group is fed with 1 g lettuce per day for two consecutive days. From the third day onwards, all groups are fed with regular mice food only.
- mice are sacrificed on the fourth day, and contents of several parts of the gastrointestinal tract, especially from the colon and cecum are collected. Presence of E. faecalis in the intestinal contents is determined by q-PCR analysis. The colon undergo fixation in order to detect putative probiotic survival by FISH methodology (Chassaing B et al., 2015. Nature. 519(7541), 92-6. doi: 10.1038/nature14232; Johansson M E et al., 2012. Methods Mol Biol. 842, 229-35. doi: 10.1007/978-1-61779-513-8_13).
Abstract
Description
- The present invention relates to edible plant tissue enriched with probiotic bacteria and use thereof for oral delivery of the probiotic bacteria to an organism and enriching and/or improving the organism gastrointestinal tract microbiome. The present invention further relates to methods for selecting and/or producing probiotic bacteria capable of colonizing a plant tissue.
- The human microbiota is the microbial community best described as “the sum of all microbial life living in or on the human body (Fricke, W. F. et al. J. Pediatr. 165, 8-10, 2014). It is an entity that has wide-reaching metabolic, nutritional, and immunological effects on the host, and as such has generated an interest within the biomedical research community. The microbiome evolves within a healthy host from birth to death, maintaining a homeostatic balance with the host's immune system. Healthy adult humans each typically harbor more than 1000 species of bacteria belonging to a relatively few known bacterial phyla with Bacteroidetes and Firmicutes being the dominant phyla (Catherine A. et al., Nature 489, 220-230, 2012). The microbiota of the gut is quite diverse compared to other body sites, and there is considerable variation in the constituents of the gut microbiota among apparently healthy individuals (Human Microbiome Project Consortium. Nature 486, 207-14, 2012). Recently, the Human Microbiome Project (HMP) reported a profound insight into the role of the microbiota in human health. For example, gut microbes train the immune system, protect against opportunistic pathogens, harvest nutrients and energy from diet, and ferment non-digestible carbohydrates. The disruption of the normal gut microbiota (dysbiosis) is associated with obesity, diabetes, various inflammatory bowel diseases (IBD) and autoimmune diseases. Many factors, either endogenous or exogenous, affect the composition of the gut microbiota. Endogenous factors include the host genotype, age, sex and both the adaptive and innate immune system. Exogenous factors include diet, exposure to medications and toxins, and illness, while diet exerts the largest impact on the gut microbiota.
- Probiotics are live microorganisms, that, when administered in adequate amounts, confer a health benefit on the host (Backhed, F. et al. Cell Host Microbe 12, 611-622, 2012). In recent decades, probiotics have been studied as a means to modulate microbial populations and functions in order to promote health and prevent or manage intestinal disorders (Ringel, Y. et al., Am. J. Gastroenterol. Suppl. 1, 34-40, 2012). Accumulated data from clinical trials indicate that certain intestinal disease conditions associated with intestinal dysbiosis, e.g. antibiotic-associated diarrhea, necrotizing enterocolitis (NEC), ulcerative colitis, inflammatory bowel syndrome (IBS) and pouchitis, have yielded clinical benefits with some probiotic interventions. Probiotics largely act directly or indirectly on the intestinal microbiota; thus, it can be assumed that some probiotics correct or reduce the effect of dysbiosis. To achieve a probiotic status, microorganisms must fulfill a number of criteria related to safety, functional effects and technological properties. Some selected strains of Lactobacillus, Bifidobacterium, Streptococcus, Lactococcus and Saccharomyces have been promoted in food products because of their reputed health benefits (Ziemer, C. J. and Gibson, G. R., Int. Dairy J. 8, 473-479, 1998; Puupponen-Pimia, R. et al., Trends Food Sci. Technol. 13, 3-11, 2002).
- Plants are a basic and substantial part of human daily diet. Vegetables, fruit, herbs, nuts, and medicinal herbs belong to the raw-eaten plant parts. Human food thus comprises all parts of plants including associated microorganisms that can be colonized by up to 104-1010 microorganisms per gram of plant. These microbial populations inhabit different habitats throughout the plant organs including the phyllosphere (lettuce, cabbage), the rhizosphere (carrots, turnip), the carposphere (tomato, banana), as well as the seeds (beans, peas) and corresponding endospheres (Berg, G. et al., in: Principles of Plant-Microbe Interactions 419-426, Springer International Publishing, 2015. doi:10.1007/978-3-319-08575-3_44).
- Endophytes are plant-endosymbiotic group of microorganisms, often bacteria or fungi. Endophytic bacteria colonize the internal tissues of plants showing no external sign of infection or negative effect on their host. The population of endophytes in a plant species is highly variable and depends on various components including, e.g., host species, host developmental stage, inoculum density and environmental condition. A distinction can be made between obligate endophytes (Croes, S. et al., Microb. Biotechnol. 6, 371-384, 2013) and facultative endophytes (Kamnev, A. A. et al., J. Trace Elem. Med. Biol. 19, 91-95, 2005). Obligate endophytes are being transmitted from the host plant to its seed; however, facultative endophytes spend only part of their life cycle in the inner tissue of plants. These endophytes enter the plant through different points including tissue wounds, stomata (pores found in the epidermis of leaves), lenticels (raised pores in the stems of woody plants), root cracks, and germinating radicals (the part of the embryo that develops into the root system). In addition, active penetration may be enabled by the secretion of pectolytic enzymes. Next, the endophytes inhabit the plant tissue either intercellular or through the vascular tubes. As mentioned above, endophytes seem to be ubiquitous in plant tissues, having been isolated from various parts of plants like flowers, fruits, leaves, stem, root, and seeds in various plant species (Indira Devi, S. and Momota, P. in Plant Microbes Symbiosis: Applied Facets 147-162, Springer India, 2015. doi:10.1007/978-81-322-2068-8_7).
- Several species of plant endophytic bacteria have been suggested to have gut probiotic properties. For example, Bacillus pumilus isolated from tissues of the medicinal plant Ocimum sanctum exhibited probiotic properties such as acid tolerance, bile salt tolerance, auto-aggregation, antibiotic resistance and the absence of haemolytic activity (Murugappan R M et al., Symbiosis 60, 91-99, 2013, DOI 10.1007/s13199-013-0244-0). Deep sequencing of a 16S rRNA gene fragment and bacterial cultivation were used to characterize the microbiomes of five plant species with edible roots revealed the presence of lactic bacteria on the pulp of Topinambur (Jerusalem artichoke, Helianthus tuberosus) (KOiv V et al., Plos One doi.org/10.1371/journal.pone.0210542 Jan. 11, 2019). U.S. Pat. No. 9,144,588 discloses biologically pure cultures of Bacillus subtilis isolated from the pericarp of nixtamalized corn, which produce peptides having antimicrobial activity. The Bacillus microorganisms may be included in probiotic food compositions to help maintain healthy gastrointestinal flora and modulate animal digestion.
- Fully utilizing the beneficial effects attributed to probiotics requires maintaining the probiotic microorganism viability during the production of oral formulations and providing gastric protection to minimize losses of viability during the transit through the stomach. Thus, there is a great need for and it would be highly advantageous to have a vehicle for delivery of probiotics answering these needs.
- The present invention provides a platform technology for producing a superior delivery vehicle of probiotic bacteria conferring a beneficial health effect on a host animal subject. The delivery vehicle is plant-based, combining highly efficient delivery of the beneficial probiotic bacteria to their site of action with the nutritional and health-promoting components of plant produce, particularly fresh plant produce.
- The technology of the present invention is based in part on the unexpected discovery that bacteria known to have probiotic effect on animal subjects can be habituated to colonize plant tissues in significant amounts and in viable form. Typically, the probiotic bacteria are habituated by selection and direct evolution and/or enrichment processes. The present invention thus provides an edible plant part or tissue enriched with probiotic bacteria colonized therein and its use for oral delivery of the bacteria. The edible plant part colonized with probiotic bacteria of the present invention is advantageous over hitherto known microbiotic delivery vehicles as, in addition to protecting the bacteria from non-favorable environmental conditions, the edible plant part by itself has high nutritional values. Edible plant tissues are rich in non-digestible or low-digestible food ingredients that benefit the animal host (prebiotics), dietary fibers, and micro- and macro-nutrients. The combination of probiotic bacteria and prebiotic characteristics of the edible plant tissue (called “synbiotics”) results in a synergic effect that selectively stimulates the growth of the probiotic bacterial community and promotes its activity in gastrointestinal tract of non-ruminant animals, specifically humans. Typically, the edible plant part is used as a fresh produce. The plant tissues provide the probiotic bacteria with suitable conditions for colonization, such that the probiotic bacteria are kept in a viable, preferably propagating form, such that high quantity of high-quality probiotic bacteria is delivered to the subject. Consequently, the probiotic bacteria are capable of affecting the structure and/or function of the recipient gastrointestinal bacterial population that is at least maintained healthy or improved to a healthier state. The plant tissue further provides protection to the probiotic bacteria from harsh environmental conditions and thus prolonging the shelf life of the bacteria. The edible plant part may be further coated with agents providing for a delayed release of the probiotic bacteria, particularly enteric coating agent(s) protecting the colonized probiotic bacteria from the acidic pH of the stomach.
- According to one aspect, the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- According to certain embodiments, the edible plant part or tissue derived therefrom comprises at least 104 colony forming units (CFU) of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- According to certain embodiments, at least 80% by weight of the edible plant part or tissue derived therefrom comprises at least 105 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- According to certain embodiments, at least 80% by weight of the edible plant part or tissue derived therefrom comprises at least 106 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- According to certain embodiments, the at least one probiotic bacteria species comprises at least 15% of the total bacteria species colonizing the edible plant part or tissue derived therefrom.
- According to certain embodiments, the probiotic bacteria are present at a site selected from the group consisting of the edible plant part or tissue intercellular space the edible plant part or tissue intracellular space, and a combination thereof. According to certain embodiments, the probiotic bacteria are further present on the edible plant part or tissue surface. According to certain exemplary embodiments, the probiotic bacteria are colonized within the intercellular and intracellular space. According to additional exemplary embodiments, the probiotic bacteria are present in the intercellular space, the intracellular space and the surface of the edible plant part or tissue.
- According to certain exemplary embodiments, the at least one probiotic bacteria species is a non-endophytic species, not previously demonstrated to colonize plant tissues.
- According to certain embodiments, the at least one probiotic bacteria species is an endophytic species capable of naturally colonizing a plant. According to these embodiments, the concentration of the enriched probiotic bacteria in the edible plant part or tissue is higher compared to the concentration of the same probiotic bacteria in a corresponding edible plant part of a control plant. The control plant is a plant to which the probiotic bacteria were not intentionally applied at any growth stage. The control plant may harbor naturally occurring probiotic bacteria without the intervention according to the present invention.
- It is to be explicitly understood that any probiotic bacterial species capable of surviving and/or proliferating in and/or on a plant tissue after been intentionally applied directly or indirectly is encompassed within the teachings of the present invention.
- The CFU of the at least one probiotic bacterial cell can be in an active state or in a dormant state.
- According to certain embodiments, the CFU of the at least one probiotic bacterial species is an active bacterial cell. According to other embodiments, the CFU is in a dormant state selected from the group consisting of a spore, a cyst and a resting-cells. According to other exemplary embodiments, the CFU of the at least one probiotic bacterial species is in a dormant form of a spore.
- According to another aspect, the present invention provides a plurality of edible plant parts or tissues derived therefrom, wherein at least 80% of the plurality of edible plant parts is enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- The edible plant part enriched with probiotic bacteria is as described hereinabove.
- Any edible plant part or tissue enabling bacterial colonization can be used according to the teachings of the present invention. According to certain embodiments, the edible plant part is selected from the group consisting of leaf, fruit, root, tuber, bulb, stem, seed and any combination thereof.
- According to certain exemplary embodiments, the edible plant part comprises prebiotic components. According to some embodiments, the prebiotic components include dietary soluble and/or insoluble fibers, including, for example, fructo-oligosaccharide. According to certain embodiments, the fructo-oligosaccharides are selected from the group consisting of, but not limited to, inulin, lactulose, and resistant starch. According to certain additional or alternative embodiments, the edible plant part comprises at least one of β-carotene, ascorbic acid, riboflavin, folic acid, iron, calcium, manganese, phosphorous, zinc and any combination thereof. According to certain additional or alternative embodiments, the edible plant part is low in calories.
- According to certain embodiments, the edible plant part is a plant fresh produce harvested from the plant. According to additional exemplary embodiments, the tissue is a fresh tissue derived from a freshly harvested edible plant part.
- According to certain embodiments, the edible plant part or tissue derived therefrom is dried. Any method as is known in the art to dry the edible plant part without negatively affecting the viability of the probiotic bacteria colonized therein can be used according to teachings of the present invention.
- It is to be explicitly understood that the edible plant part or the tissue derived therefrom are not fermented.
- According to certain exemplary embodiments, the edible plant part is a leafy produce of the plant, including, but not limited to, lettuce, spinach, endive, chard and arugula.
- According to certain embodiments, the probiotic bacteria are gram positive bacteria. According to certain embodiments, the probiotic bacteria are gram negative bacteria. According to some embodiments, the probiotic bacteria are of a genus selected from the group consisting of Enterococcus, Bifidobacterium, Lactobacillus, Propionobacterium, Bacillus, Streptococcus, Pediococcus, Escherichia, Leuconostoc, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the probiotic bacteria are of a species selected from the group consisting of Enterococcus faecalis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus rhamnosus, Lactobacillus casei B, Bacillus subtilis and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain exemplary embodiments, the probiotic bacteria are of a species selected from the group consisting of Enterococcus faecalis, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus salivarius, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the edible plant part enriched with the colonized probiotic bacteria or the tissue derived therefrom is coated with a suitable agent and or formulation providing for a delayed release of the bacteria. According to certain exemplary embodiments, the coating comprises enteric coating protecting the plant tissues from the acidic pH of the stomach. Once the entering coating is dissolved in the intestine, the edible plant tissues are amenable to digestion by microbiota already present in the intestine and the delivered probiotic bacteria are released. According to certain embodiments, the edible plant part or tissue derived therefrom is coated with enteric coating when the probiotic bacteria are beneficially active in the intestine.
- The present invention discloses for the first time that an edible plant part or a tissue derived therefrom coated with enteric coating can be used for oral delivery of a biologically active ingredient present therein, wherein the active ingredient reaches the intestine in its active form. The enteric coating prevents digestion of the edible plant tissue within the stomach, and thus prevents exposure of the biologically active ingredient to the acidic, harmful pH of the stomach. Upon elevation of the pH in the intestine, the entering coating is dissolved, exposing the plant tissue to digestion and release of the active ingredient stored therein.
- Thus, according to additional aspect, the present invention provides an edible plant part or a tissue derived therefrom comprising at least one biologically active agent, coated with enteric coating.
- According to certain embodiments, the biologically active agent is probiotic bacteria. According to some embodiments, the coated edible plant part or tissue derived therefrom further comprises at least one additional active agent selected from the group consisting of a nutritionally active agent, a therapeutically active agent and a combination thereof. According to certain embodiments, the additional active agent is a by-product of the presence of the probiotic bacteria.
- Any enteric coating agent or combination of agents known in the art to be resistant to the acidic pH of the stomach of non-ruminant mammals and to be dissolved in the higher pH of the intestine can be used according to the teachings of the present invention. According to certain exemplary embodiments, the enteric coating comprises Cellulose Acetate Phthalate (CAP).
- According to additional aspect, the present invention provides a method for oral delivery of probiotic bacteria to a subject in need thereof, the method comprising orally administering to the subject an effective amount of an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of said subject.
- According to additional aspect, the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of said subject for use in a method for oral delivering to a subject an effective amount of the probiotic bacteria.
- The edible plant part or tissue enriched with the probiotic bacteria are as described hereinabove.
- According to certain embodiments, the edible plant part or tissue derived therefrom enriched with at least one colonized probiotic bacterial species is coated with enteric coating.
- According to certain embodiments, the probiotic bacteria reach the subject intestine. According to some embodiments, the probiotic bacteria propagate in the subject intestine.
- According to certain embodiment, the method results in altering the subject gastrointestinal microbiota profile compared to the profile before administering to said subject the edible plant part or tissue derived therefrom enriched with the at least one probiotic bacterial species.
- According to yet additional or alternative embodiments, the method results in a beneficial therapeutic effect. According to certain embodiments, the therapeutic effect comprises treating or preventing GI-related disease or disorder.
- An initial bacteria load of 107 CFU/g is recommended for probiotic food, for example, yogurt. The high numbers have been suggested to compensate for the possible loss in the numbers of the probiotic bacteria during passage through the stomach and intestine. Preferably, even a higher bacteria load of 1010 CFU/g of yogurt is used to ensure delivery of a greater number of live probiotic bacteria to the target sites, e.g. small intestines and colon. The plant-based delivery vehicle of the present invention may enable several magnitude lower load of the probiotic bacteria, as the plant tissue provide the bacteria both with protection through the GI passage and initial energy source at the site of activity, enabling immediate proliferation of the probiotic bacteria at the site of action.
- According to yet additional or alternative embodiments, the method results in a beneficial cosmetic effect. According to certain embodiments, the cosmetic effect comprises regulation of skin appearance. According to some embodiments, skin appearance regulation includes, but is not limited to, reduction of skin acne, reduction of skin flaking and reduction of signs of skin aging. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the subject is a non-ruminant mammal. According to certain exemplary embodiments, the subject is human.
- The edible plant part, tissue derived therefrom, the probiotic bacteria and the entering coating are as described hereinabove.
- According to additional aspect, the present invention provides a method for selecting and/or producing probiotic bacterial species having endophytic characteristics of being capable of growing in a plant tissue, the method comprising:
-
- a) applying to a plant or a part thereof an effective amount of at least one species of probiotic bacteria known to only inhabit animal gastrointestinal tract;
- b) growing the plant or part thereof under conditions enabling augmentation of at least one leaf and/or emergence of at least one new leaf;
- c) isolating bacteria from the at least one augmented and/or newly emerged leaf;
- d) identifying the isolated bacteria; and
- e) selecting bacteria of the probiotic species applied in step (a) or strains derived thereof, said probiotic bacteria are capable of growing in a plant.
- According to certain embodiments, the method is repeated at least once as to confirm the capability of the selected probiotic bacteria to colonize in a plant.
- It is to be explicitly understood that the method of the present invention for selecting probiotic bacterial species capable of colonizing plant tissues encompasses isolating bacteria from augmented leaf a week after inoculation and/or from newly developed plant tissues that are not directly inoculated with the probiotic bacteria. Thus, only bacteria that can survive, propagate and spread within the plant tissue are selected, optimizing the selection of probiotic bacteria to be used according to the teachings of the present invention.
- The selected probiotic bacteria capable of colonizing a plant tissue can be identical to the bacteria strain initially applied to the plant or part thereof, or can exhibit modified characteristics and thus be identified as modified strain or even as a new strain of bacteria, with the proviso that the modified or new strain exhibit probiotic characteristics.
- According to another aspect, the present invention provides a method for producing an edible plant part enriched with at least one probiotic bacteria species capable of inhabiting the gastrointestinal (GI) tract of an animal, the method comprising:
-
- a. applying to a plant or a part thereof the at least one bacteria species;
- b. growing the plant or part thereof to obtain a plant producing the edible plant part; and
- c. harvesting the edible plant part, said edible plant part is enriched with the at least one bacterial species.
- According to certain embodiments, the method further comprises the steps of:
-
- i. isolating the at least one bacterial species from the leaves or stem of the plant of step (b);
- ii. propagating the isolated at least one bacteria species of step (i);
- iii. applying the propagated bacteria of step (ii) to a plant or a part thereof; and
- iv. repeating step (b).
- According to certain embodiments, steps (i)-(iii) are repeated at least once.
- According to certain embodiments, the plant part is selected from the group consisting of seeds, stems and leaves. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the plant part is a seed.
- Any method as is known in the art for applying the at least one probiotic bacterial species to the plant or part thereof can be used according to the teachings of the present invention. According to certain exemplary embodiments, the at least one probiotic bacterial species is suspended in a liquid. According to certain embodiments, the liquid is water. According to other embodiments, the liquid is a culture medium. According to certain embodiments, the liquid is applied to the plant or part thereof by a method selected from the group consisting of infiltration, immersion/dipping, incubation, spraying, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the plant part is a seed. According to certain embodiments, the at least one probiotic bacterial species is applied to the seed via seed coating. According to certain exemplary embodiments, a plurality of seeds is coated with a seed coating agent comprising the at least probiotic bacterial species. According to these embodiments, a plurality of plants is grown from the plurality of seeds.
- It is to be understood that any combination of each of the aspects and the embodiments disclosed herein is explicitly encompassed within the disclosure of the present invention.
- Other objects, features and advantages of the present invention will become clear from the following description and drawings.
-
FIG. 1 shows partitioning of the introduced bacteria to epiphytes and endophytes in leaves of plantlets developed from seeds coated with carboximetilcelulose (CMC)-probiotic bacteria mixture, when separation is performed by sonication. The probiotic bacteria used were E. Faecalis, L. Paracasei, and B. subtilis. Each analysis was performed in quadruplicate; error bars represent standard error of the mean (n=4). -
FIG. 2 shows the survival percentage of original probiotic isolates of E. Faecalis (FIG. 2A ), L. Paracasei (FIG. 2B ), and B. subtilis (FIG. 2C ) [obtained from the American Type Culture Collection (ATCC) bank] compared to the survival percentage of same isolate species isolated from lettuce plant (after 7 growth cycles) exposed to solution simulating gastric fluid (SGF) containing Pepsin at pH=2 or pH=4. -
FIG. 3 shows the survival percentage of original (obtained from ATCC bank) probiotic isolates of E. Faecalis (EF), L. Paracasei (LP), and B. subtilis (BS) compared to the survival percentage of same isolate species isolated from lettuce plant (after 7 growth cycles) exposed to solution simulating intestinal fluid (SIF) containing pancreatic enzymes for 120 or 240 min at 37° C. and at pH=6.8. -
FIG. 4 shows E. Faecalis establishment in lettuce leaves of plant developed from coated seeds after 8, 13, 20 and 28 days. Each analysis was performed in quadruplicate. error bars represent standard error of the mean (n=4). -
FIG. 5 demonstrates the survival of Enterococcus faecalis bacteria applied to lettuce cut leaves by dipping the leaves in a solution comprising the bacteria with or without CMC. *indicate significant differences (p<0.05); error bars represent standard error of the mean (n=10). - Gut probiotics are live microbes that beneficially affect an animal host by modulating mucosal and systemic immunity, as well as improving intestinal function and microbial balance in the gastrointestinal tract. Various nutritional and therapeutic effects have been ascribed to probiotics including: modulating immune response, lowering serum cholesterol concentrations, improving lactose intolerance symptoms, increasing resistance to infectious intestinal diseases, decreasing duration of diarrhea, reducing blood pressure, and helping to prevent colon cancer. In order to exert their beneficial effects on the host, probiotics must remain viable and reach the intestine in large numbers.
- The present invention provides a platform technology providing plant material that is a vehicle for orally delivering beneficial probiotic bacterial species to the gastrointestinal tract, and particularly to the intestine of a non-ruminant animal subject in need thereof. The plant material is typically fresh produce which by itself provides healthy food ingredients including dietary fibers, vitamins, micro- and macronutrients. According to certain embodiments, the plant part is leafy fresh produce, which is also low in calories. Furthermore, the plant material comprises prebiotic ingredients that induce the growth or activity of the probiotic bacteria once reaching the subject gastrointestinal tract.
- All plants are inhabited internally by diverse microbial communities comprising bacterial, archaeal, fungal, and protistic taxa. Bacteria are associated with plants in various ways, part of which leading to plant diseases and damage to the plant life, but part having beneficial effects on the plant growth and characteristics. Endophytic bacteria are generally defined as bacteria colonizing plants without causing visible harm. Endophytic bacteria benefits from their host plant, receiving a constant food supply and being sheltered from environmental stress. In exchange, bacterial endophytes may offer several benefits to the host plant, particularly growth promotion in terms of increased germination rates, biomass, leaf area, chlorophyll content, nitrogen and protein content, hydraulic activity, yield and tolerance to abiotic stresses. Some endophytes protect their host plant from pathogens and can act as biocontrol agents.
- The terms “endophyte” and “endophytic” with reference to bacteria refers to bacteria capable of colonizing plants without causing visible harm to the plant. Endophytic bacteria can be obligate endophytes, i.e. bacteria that live within plant tissues for the entirety of its life cycle or facultative (transient), i.e. bacteria which may spend only part of the life cycle within the plant.
- The terms “probiotic bacteria”, “gut probiotic bacteria”, and “probiotic bacteria capable of inhabiting the gastrointestinal (GI) tract of an animal” are used herein interchangeably and refer to non-pathogenic bacteria that beneficially affect a non-ruminant animal subject by improving the intestinal microbial balance. In some embodiments, the probiotic bacteria have therapeutic beneficial effect in preventing and/or treating a disease or disorder. In some embodiments, the probiotic bacteria have a nutritional beneficial effect. In yet additional embodiments, the probiotic bacteria improve the general well-being of the subject consuming same.
- The term “prebiotic” as used herein is directed to compounds (for example, dietary compounds in food) that can induce or aid with the growth or activity of probiotic microorganism. In some examples, a prebiotic is a substrate that is selectively used by a microorganism, or selectively affect the microorganism. According to the teachings of the present invention, the prebiotic is an edible plant tissue or a compound derived therefrom.
- As used herein, the terms “exogenously applied” and “intentionally applied” refer to the application of isolated gut probiotic bacteria of at least one species, or of an agricultural composition comprising same. It is to be explicitly understood that the probiotic bacteria to be applied are enriched with the desired isolate species or plurality of species. Accordingly, application of agricultural compositions contaminated with probiotic bacteria (for example manure used for fertilization, manure-contaminated irrigation water) is referred to herein as unintentional application and is specifically excluded from the teachings of the present invention.
- The terms “colony forming unit” and CFU (in single or plural) are used herein interchangeably as an indicative number of viable bacteria.
- The terms “comprise”, “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.
- As used herein the term “about” in reference to a numerical value stated herein is to be understood as the stated value +/−10%.
- As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.
- According to one aspect, the present invention provides an edible plant part or a tissue derived therefrom enriched with probiotic bacteria of at least one species colonizing the edible plant part or tissue derived therefrom, wherein the probiotic bacteria are capable of inhabiting the gastrointestinal (GI) tract of an animal.
- The edible plant part or tissue may be enriched with one genus and/or species and/or strain of probiotic bacteria or with a combination thereof. According to the teachings of the present invention the probiotic bacteria are gut bacteria, i.e. bacteria found in the gut microbiome of a non-ruminant animal. In some embodiments, the plant part or tissue may be enriched with various species or strains present at equal amounts or at different amounts, at equal or different proportions.
- The present invention is based in part on the application of isolated probiotic bacteria enriched for selected species or plurality of species to a plant or a part thereof which results in the enrichment of an edible part of the plant with the probiotic bacteria species or plurality of species.
- According to certain embodiments, the at least one probiotic bacteria species comprise at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23% at least 24% at least 25% at least 26% at least 27% at least 28% at least 29% at least 30% or more of the total bacteria species colonizing the edible plant part or tissue derived therefrom.
- According to certain embodiments, the edible plant part or tissue derived therefrom comprises at least 104 colony forming units (CFU) of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- According to certain embodiments the edible plant part or tissue derived therefrom comprises from about 104 CFU/g plant tissue to about 1011 CFU/g plant tissue or any subranges thereof. According to certain embodiments, the amount of probiotic bacteria can range from about 104 CFU/g to about 5×1010 CFU/g, or from about 104 CFU/g to about 109 CFU/g, or from about 106 CFU/g to about 5×109 CFU/g. According to certain exemplary embodiments, the amount of probiotic bacteria ranges from about 104 CFU/g plant tissue to about 108 CFU/g plant tissue.
- According to certain embodiments, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% by weight of the edible plant part or tissue derived therefrom comprises at least 105 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- According to certain embodiments, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% by weight of the edible plant part or tissue derived therefrom comprises at least 106 CFU of the probiotic bacteria per gram of the edible plant part or tissue derived therefrom.
- The terms “colony forming unit” and “CFU” are used herein interchangeably in its broadest meaning in the art. According to certain embodiments, the CFU of the at least one probiotic bacterial species is a bacterial cell in an active state. According to certain embodiments the CFU of the at least one probiotic bacterial species is in a dormant state selected from the group consisting of a bacterial spore, a bacterial cyst and a bacterial resting-cell.
- According to certain exemplary embodiments, the at least one probiotic bacteria species has not been previously demonstrated to colonize plant tissues, and thus are define as non-endophytic bacteria.
- According to certain embodiments, the probiotic bacteria are of endophytic bacteria species capable of naturally colonizing a plant. According to these embodiments, the concentration of the enriched probiotic bacteria in the edible plant part or tissue is higher compared to the concentration of the same probiotic bacteria in a corresponding edible plant part of a control plant. The control plant is a plant to which the probiotic bacteria were not intentionally applied at any growth stage. The control plant may harbor naturally occurring probiotic bacteria without the intervention according to the present invention, but at a lower amount and/or at a different species composition and/or at a different species proportions.
- According to certain aspects, the present invention provides methods for selecting and/or producing probiotic bacterial species capable of colonizing in plants. The present invention further provides methods for enriching an edible plant part or tissue with the probiotic bacteria that acquired the capability to grow and proliferate within plant tissues.
- As described hereinabove, probiotics as functional food components should demonstrate diverse properties. Importantly, no adverse effects may be associated with the presence of the bacterial species in the animal body. The majority of bacteria belonging to the Lactobacillus and Bifidobacterium genera are recognized as safe and beneficial as probiotics. Lactobacillus and Bifidobacterium genera are normal residents of the microbiota in the human gastrointestinal tract, in which they develop soon after birth. It is generally accepted that, with the only exception of streptococci and enterococci, lactic acid bacteria are rarely pathogenic to humans and animals. Specific strains of Enterococcus, E. faecium and E. faecalis are the only enterococci used as probiotics or feed additives (Franz C M et al., 2011. Int. J. Food Microbiol. 151, 125-140). These bacteria have been used in production of foods since ancient times with no negative effects on humans (Grajek, W. et al., Present. Int. Rev. Conf. Biotechnol, 2004). It is surmised that probiotic bacteria positively affect the human health through a wide variety of different putative mechanisms. They involve the reinforcement of the intestinal barrier, alterations of the immune response, and development of antagonism to pathogens either by the production of antimicrobial compounds or throughout competitive activities towards mucosal binding sites (Ouwehand, A. C. et al., Int. Dairy J. 9, 43-52, 1999).
- Any bacterial species and/or strain known to have a beneficial probiotic activity when present in the gastrointestinal tract of a non-ruminant mammal, particularly human subject can be used according to the teachings of the present invention.
- According to certain embodiments, the probiotic bacteria are gram positive bacteria. According to certain embodiments, the probiotic bacteria are gram negative bacteria. Several genera of bacteria are known to have probiotic activity (Fijan S. International journal of environmental research and public health 11(5), 4745-4767, 2014). According to some embodiments, the probiotic bacteria are of a mammal not pathogenic genus selected from the group consisting of Enterococcus, Bifidobacterium, Lactobacillus, Propionobacterium, Bacillus, Streptococcus, Pediococcus Escherichia, Leuconostoc, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the probiotic bacteria are of the species Enterococcus faecalis.
- According to certain embodiments, the probiotic bacteria are of the species, Lactobacillus paracasei.
- According to certain embodiments, the probiotic bacteria comprises a combination of Enterococcus faecalis and Lactobacillus paracasei. According to certain embodiments, the method of the present invention for selecting and/or producing probiotic bacterial species capable of growing in a plant comprises the following steps:
-
- a) applying to a plant or a part thereof an effective amount of at least one species of gut probiotic bacteria;
- b) growing the plant or part thereof under conditions enabling augmentation of at least one leaf and/or emergence of at least one new leaf;
- c) isolating bacteria from the at least one augmented and/or newly emerged leaf;
- d) identifying the isolated bacteria; and
- e) selecting bacteria of the probiotic species applied in step (a) or strains derived therefrom, said probiotic bacteria are capable of growing in a plant.
- According to certain embodiments, the plant part is selected from the group consisting of seeds and leaves.
- According to certain exemplary embodiments, the method is repeated at least once as to confirm the capability of the selected probiotic bacteria to grow in a plant, specifically to colonize the intercellular and intracellular space of the plant tissues.
- Any method as is known in the art for applying the at least one probiotic bacterial species to the plant or part thereof can be used according to the teachings of the present invention. According to certain exemplary embodiments, the at least one probiotic bacterial species is suspended in a liquid. According to certain embodiments, the liquid is applied to the plant or part thereof by a method selected from the group consisting of infiltration, immersion/dipping, incubation, spraying, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- According to certain embodiments, the plant part is a seed. According to certain embodiments, the at least one probiotic bacterial species is applied to the seed via seed coating. According to certain exemplary embodiments, a plurality of seeds is coated with a seed coating formulation comprising the at least probiotic bacterial species. According to these embodiments, a plurality of plants is grown from the plurality of seeds.
- Any seed coating formulation compatible for bacterial growth can be used according to the teachings of the present invention. According to some embodiments, the seed coating formulation comprises at least one adherent selected from the group consisting of carboxymethyl cellulose, alginate, gums, starches, lecithins, formononetin, polyvinyl alcohol, alkali formononetinate, hesperetin, polyvinyl acetate, cephalins, Gum Arabic, Xanthan Gum, Mineral Oil, Polyethylene Glycol (PEG), Polyvinyl pyrrolidone (PVP), Arabino-galactan, Methyl Cellulose, PEG 400, Chitosan, Polyacrylamide, Polyacrylate, Polyacrylonitrile, Glycerol, Triethylene glycol, Vinyl Acetate, Gellan Gum, Polystyrene, Polyvinyl, Gum Ghatti, and polyoxyethylene-polyoxybutylene block copolymers. Each possibility represents a separate embodiment of the present invention. According to certain exemplary embodiments, the coating formulation comprises carboxymethyl cellulose.
- The method of the present invention for selecting probiotic bacteria encompasses selection of the bacteria from plant part(s) or tissues not necessarily directly inoculated. This type of selection is of high significance, as the selected bacteria can survive, propagate and spread within the plant tissues, indicating valid endophytic characteristics.
- It is to be explicitly understood that the bacteria selected at step (e) may be identical to the bacteria applied to the plant or part thereof at step (a), or the selected bacteria may comprise genetic variation compared to the bacteria first applied. According to these embodiments, modified or new sub-strains may be produced.
- Only bacterial species capable of surviving and/or proliferating in a plant tissue and having beneficial probiotic characteristics can be used according to the teachings of the present invention. Accordingly, the probiotic characteristic of the modified or new sub-strains are examined, using any suitable model as is known in the art. According to certain embodiments, a mice model system is used to validate the probiotic characteristics of the modified or new sub-strain.
- According to certain aspects, the present invention provides an edible plant part or a tissue derived therefrom enriched with at least one probiotic bacterial species selected or produced according to the method of the invention.
- According to another aspect, the present invention provides a method for producing an edible plant part enriched with at least one probiotic bacteria species capable of inhabiting the gastrointestinal (GI) tract of an animal, the method comprising:
-
- a. applying to a plant or a part thereof the at least one bacteria species;
- b. growing the plant or part thereof to obtain a plant producing the edible plant part; and
- c. harvesting the edible plant part, said edible plant part is enriched with the at least one bacterial species.
- According to certain embodiments, the method further comprises the steps of:
-
- i. isolating the at least one bacterial species from the leaves or stem of the plant of step (b);
- ii. propagating the isolated at least one bacteria species of step (i);
- iii. applying the propagated bacteria of step (ii) to a plant or a part thereof; and
- iv. repeating step (b).
- According to certain embodiments, steps (i)-(iii) are repeated at least once.
- The plant part to which the probiotic bacteria are applied and the methods of application are as described hereinabove.
- As described hereinabove, the present invention harnesses the phenomenon of endophytic bacteria to provide a superior vehicle for oral delivery of probiotic bacteria to non-ruminant animal, particularly to humans.
- The plant provides the probiotic endophytic bacteria with the environmental conditions required for the bacteria colonization and propagation. The colonized probiotic bacteria are delivered to the subjects within edible parts of the plant, typically fresh, such that there is no need to take any special measures to keep the probiotic bacteria alive until consumption. Furthermore, the plant tissues protect the probiotic bacteria, providing a sort of an encapsulation, such that significant number of viable probiotic bacteria reach their site of action. Accordingly, even relatively low number of the probiotic bacteria present in the edible plant part results in an effective number within the GI of the subject consuming same.
- Furthermore, plant fresh produce (including fruit, vegetables, tubers, bulbs and leafy produce) are the most important raw-eaten food worldwide and are a substantial part of a balanced and healthy diet. Many beneficial effects on health and lifestyle are attributed to the consumption of fresh-cut or minimally processed edible plant products as they represent a good source of vitamins, e.g. β-carotene, ascorbic acid, riboflavin and folic acid as well as minerals, e.g. iron, calcium, manganese and phosphorous. Moreover, plant fresh produce is known to be rich sources of micronutrients as well as dietary fiber, particularly in leafy produce, enabling the intake of these nutrients. Finally, the relatively low amount of carbohydrates and fats, particularly in vegetables and leafy foods correlates with a low calorie value, making them leading candidates for healthy diet. In addition, the presence of non-digestible or low-digestible food ingredient characterizes plant fresh produce as prebiotic substance, stimulating the growth or activity of beneficial probiotic bacteria in the human colon (Biedrzycka B., Polish J. food Nutr. Sci. 13, 143-150, 2004).
- According to certain embodiments, the probiotic bacteria are present at a site selected from the group consisting of the edible plant part or tissue intercellular space, the edible plant part or tissue intracellular space and a combination thereof. According to some embodiments, the prebiotic bacteria are further present on the edible plant part or tissues surface. According to certain exemplary embodiments, the probiotic bacteria are colonized within the intercellular and/or intracellular space.
- According to certain embodiments, the edible plant part comprises the at least one probiotic bacterial species actively growing. According to other embodiments, the edible plant part comprises the at least one probiotic bacterial species in its dormant form.
- According to certain embodiments, the edible plant part is selected from the group consisting of leaf, stem, fruit, root, tuber, bulb, seed and any combination thereof.
- According to certain exemplary embodiments, the edible plant part is rich in dietary fibers. According to certain additional or alternative embodiments, the edible plant part is rich in prebiotic components. According to certain additional or alternative embodiments, the edible plant part is rich in at least one of β-carotene, ascorbic acid, riboflavin, folic acid, iron, calcium, manganese, phosphorous, zinc and any combination thereof. According to certain additional or alternative embodiments, the edible plant part is low in calories.
- According to certain exemplary embodiments, the edible plant part is a leafy produce of the plant.
- According to certain exemplary embodiments, the probiotic bacteria are of a species selected from the group consisting of Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus salivarius, Enterococcus faecalis, and any combination thereof. Each possibility represents a separate embodiment of the present invention.
- As described hereinabove, additional advantage of the plant-derived edible vehicle of probiotic bacteria of the present invention is that the plant tissues provide protection to the probiotic bacteria from unfavorable environmental conditions and further at least partial protection to the bacteria through the transit via the stomach to the intestine.
- To further protect the probiotic bacteria, the present invention now discloses coating the edible plant part or tissue derived therefrom with a suitable coating to obtain a delayed release of the probiotic bacteria, so as to avoid exposure of the probiotic bacteria to the acidic pH of the stomach. As used herein the term “delayed release” refers to a time delay between oral administration of the edible plant part or tissue enriched with the probiotic bacteria and the release of said bacteria from the plant part or tissue. “Delayed release” may or may not involve gradual release of the probiotic bacteria over an extended period of time, and thus may or may not be “sustained release”.
- According to certain embodiments, the coating is enteric coating.
- Enteric-coated formulations are suitable vehicles for modification of the release of drug or active agent at specific target areas within the gastrointestinal tract. Enteric coating is an effective method of protecting the drug or agent against a gastric environment and preventing its release before reaching the target site. Therefore, enteric polymer-coated formulations have been developed to prevent acid degradation in the stomach. In addition, the enteric coating must be readily soluble in alkaline buffer so that the drug or active agent is readily available for systemic absorption. Enteric polymers can be divided into three categories: (i) modified cellulosic derivatives e.g., cellulose acetate phthalate, hypromellose phthalate, hypromellose acetate succinate and (ii) methyl acrylate-methacrylic acid copolymers and (iii) other materials e.g., Shellac, polyvinyl acetate phthalate (Caillard, R. et al., Int. J. Pharm. 499, 321-329, 2016).
- Cellulose acetate phthalate (CAP) has been used as an enteric coating material due to its non-ionized form which predominates in acid but becomes soluble once the phthalic acid groups become ionized above pH 6 (Balamuralidhara, V. et al., Am. J. drug Discov. Dev. 1, 24-48, 2011). CAP contains about 35% phthalyl and 24% acetyl groups (U.S. Pat. Nos. 4,960,814 and 5,025,004). It has been described that one carboxyl of the phthalic acid is combined with cellulose, and the other is free for further reactions. The resulting polymeric acid forms water-soluble alkaline salts. CAP was further clinically tested and was demonstrated not to have toxic effects, and to be remarkably inert as a compound of the diet. Moreover, there is no evidence in the laboratory and manufacturing handling of this product to indicate any allergenic or sensitizing effects (Hodge, H. C. J. Pharmacol. Exp. Ther. 80, 1944). Recent studies by Sachdeva et al. have been performed on the production of enteric-coated biochanin A microparticles and their pharmacological potential was investigated in hypertensive ovariectomized rats (Ovx-HT) (Sachdeva, C. et al., Drug Deliv. 23, 2044-205, 2016). The authors concluded that the enteric-coating of biochanin A exhibited delayed release capacity, an increase in oral bioavailability up to 6 folds than plain biochanin A and antihypertensive effect in ovariectomized rats possibly in an eNOS dependent manner Other studies have reported that the CAP coated oral tablet formulations successfully enabled the delivery of drug to the intestine where the alkaline environment dissolves the protective coating (Sachdeva, et al., 2016, ibid; Bertz, A. et al., J. Biotechnol. 163, 243-249, 2013; Wong, C. Y. et al., J. Pharm. Pharmacol. 69, 285-294, 2017).
- According to certain aspects, the present invention provides an edible plant part or a tissue derived therefrom comprising a biologically active agent, coated with enteric coating.
- The present invention encompasses coated edible plant parts or tissues comprising any biologically active agent that can habitat the edible plant part or be expressed therein. According to certain embodiments, the biologically active ingredient is selected from the group consisting of a nutritionally active agent, a therapeutically active agent and a combination thereof.
- According to certain embodiments, the biologically active agent is endogenous to the edible plant part. According to other embodiments, the biologically active agent is heterologous to the edible plant part.
- According to certain embodiments, the biologically active agent is probiotic bacteria.
- According to certain additional or alternative embodiments, the biologically active agent is selected from the group consisting of a protein, a polynucleotide, a vitamin, a chemotherapeutic agent, an anti-oxidant, an anti-aging agent.
- According to additional aspect, the present invention provides a food product comprising a plant tissue enriched with at least one probiotic bacterial species according to the teachings of the invention or a lysate thereof.
- According to yet additional aspect, the present invention provides an oral formulation comprising a plant tissue enriched with the at least one probiotic bacterial species according to the teachings of the invention or a lysate thereof.
- The plant tissue can be in a form selected from the group consisting of intact tissue, cut tissue, grinded tissue, and any combination thereof. Typically, the plant tissue is fresh, but may be present in other forms including frozen and dried form, as long as the probiotic bacteria preserve the ability to propagate once reaching a subject intestine.
- Any food product or an oral formulation as is known in the art can be used according to the teachings of the present invention.
- According to certain embodiments, the oral formulation is a liquid formulation selected from the group consisting of suspensions, elixirs and solutions. According to certain embodiments, the oral formulation is a solid formulation selected from the group consisting of powders, tablets, capsules and pills.
- The plant tissue and the probiotic bacteria are as described hereinabove.
- According to additional aspects, the present invention provides a method for oral delivery of at least one species of gut probiotic bacteria to a subject in need thereof, the method comprising orally administering to the subject an effective amount of an edible plant part or a tissue derived therefrom enriched with the gut probiotic bacteria.
- According to further aspects, the present invention provides an edible plant part or a tissue derived therefrom enriched with at least one gut probiotic bacteria species for use in oral delivery of an effective amount of the probiotic bacteria to a subject.
- According to further aspects, the present invention provides use of an edible plant part or a tissue derived therefrom enriched with at least one gut probiotic bacteria species for oral delivery of the probiotic bacteria.
- According to certain embodiments, the edible plant part or tissue derived therefrom enriched with at least one probiotic bacteria species is coated with enteric coating.
- According to certain embodiments, the probiotic bacteria reach the intestine of a subject consuming the plant or part thereof. According to some embodiments, the probiotic bacteria propagate in the subject intestine.
- According to certain embodiments, oral delivery of the edible plant part or tissue enriched with the probiotic bacteria results in altering the gastrointestinal microbiota profile of a subject consuming the edible plant part or tissue compared to the profile before consumption.
- According to certain embodiments, oral delivery of the edible plant part or tissue provides a beneficial therapeutic effect to the subject.
- According to certain embodiment's, the therapeutic effect comprises comprising treating or preventing GI-related disease or disorder.
- Oral administration of the edible plant part or tissue enriched with probiotic bacteria according to the teachings of the present invention may have a therapeutic effect in treating and/or preventing gastrointestinal tract related diseases or disorder, including, but not limited to diarrhea, diarrhea caused by antibiotic, arthritis, obesity, irritable bowel syndrome (IBS), cancer, heartburn, offset lactose intolerance; chronic fatigue syndrome and other forms of suffering from an unbalanced bacterial population in the intestine; in repopulation of the gut microbiome after antibiotic therapy; in inhibiting pathogenic bacteria; in supporting the immune system; in reducing cholesterol; in enhancing the bio-availability of calcium, zinc, iron, manganese, copper and phosphorus; and in synthesis of vitamins. Non-limiting examples of a subject receiving and benefiting from such an oral administration include a non-ruminant mammal including human or a domestic animal or a farm animal such as cats, dogs, pigs, poultry or fish.
- According to certain embodiments, oral delivery of the edible plant part or tissue provides a beneficial cosmetic effect to the subject.
- According to yet another aspect, the present invention provides a cosmetic method comprising topically administering to a subject in need thereof a plant tissue enriched with at least one probiotic bacteria species or a lysate thereof. It is to be explicitly understood that the lysate comprises a cosmetically effective amount of the probiotic bacteria. The lysate can be prepared by any method as is known in the art.
- The at least one probiotic bacterial species is as described hereinabove.
- According to certain embodiments, the subject is a non-ruminant mammal.
- According to certain exemplary embodiments, the subject is a human.
- The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.
- Several probiotic bacteria species known to be capable of growing in the GI of an animal and have health beneficial effects were selected to be introduced into plant tissues. Enterococcus faecalis, Lactobacillus paracasei, Lactobacillus acidophilus, Lactobacillus salivarius, Streptococcus thermophiles and Bacillus subtilis, belonging to different bacterial families, were purchased from ATTC and grown in culture in optimal conditions (Lactobacilli MRS agar (BD Difco), supporting growth of all lactobacilli; or Brain Heart Infusion (BHI, BD Difco) agar, general-purpose medium for the growth of a wide variety of bacteria, at 37° C.). Each bacteria species was collected from the agar plate and re-suspended in PBS to achieve a final concentration of 106 CFU/ml.
- A bacterial culture of Lactobacillus paracasei obtained as described hereinabove was infiltrated into leaves of lettuce plantlets at a volume of about 1 ml (culture O.D=0.1 at 600 nm). After infiltration the plants were grown in growth chamber at 27° C. with long day period of 12 hours of light.
- After 10 days, samples (leaf pieces) from the infiltrated leaf and from new emerging leaves were collected. The bacteria were extracted from each sample by grinding the leaves in PBS using a crater and pestle and directly plating the resulted mixture using serial dilutions on selective medium. The different colonies that grew in the medium were identified by sequencing of 16S rRNA gene. Table 1 shows exemplary results for the assay performed with Lactobacillus paracasei.
-
TABLE 1 Quantification and identification of probiotic strain isolated from lettuce leaf ten-days post infiltration Number of CFU/ml Number of CFU/ml in infiltrated in new emerging Bacterial species lettuce leaves lettuce leaves infiltrated into (percentage of (percentage of 16S rRNA gene lettuce plantlets inhabited leaves) inhabited leaves) identification Lactobacillus paracasei 2.86*104 7.2*103 L. paracasei (100%) (66%) - Enterococcus faecalis, Lactobacillus paracasei, and Bacillus subtilis were grown in culture in optimal conditions as described hereinabove to achieve a final concentration of 106 CFU/ml. Each bacteria species was collected from the agar plate and blended with 2% carboximetilcelulose (CMC) (Song, Y et al., J. Agric. Sci. 6, 132, 2014) with vigorous shaking in order to achieve a homogenous suspension with a final concentration of 107-108 CFU/ml. CMC is a food-grade substance, approved by the US Food and Drug Administration (FDA) for use in food products.
- Lettuce seeds were coated with the suspension of bacteria and CMC. The coated seeds were germinated in aseptic system of Hoagland No. 2 basal salt mixture agar (pH 6.5) and grown in a Plant Growing Room set to 22° C. and long day period of 12 hours of light.
- After 9 days, leaf samples of plants developed from the coated seeds were collected. The bacteria were extracted from each sample by grinding the leaves in Saline using a crater and pestle. The resulted mixture was plated on BHI agar medium. Colonies that grew on the supportive medium were identified by sequencing of 16S rRNA gene. The number of CFU/ml medium for each bacterial species is presented in Table 2 hereinbelow.
-
TABLE 2 Quantification and identification of probiotic strains isolated from leaves of lettuce developed from coated seeds Bacterial species Number of CFU/ml Number of CFU/ml 16S rRNA gene coated onto lettuce seed coating solution in lettuce leaf identification Lactobacillus paracasei 5*108 3.72*105 L. paracasei Enterococcus faecalis 12*108 1.53*106 E. faecalis Lactobacillus salivarius 10*108 2.84*104 L. salivarius - Applying gut probiotic bacteria to plants via immersion of the bacteria in hydroponic media for plant growth requires that the gut probiotic bacteria can grow in the hydroponic medium, which typically includes fertilizers. Candidate probiotic bacteria or probiotic bacteria already shown to have the capability of endophytic growth are grown to form cell culture as described hereinabove. Plant hydroponic medium is inoculated with the bacteria culture and left to grow within the medium under conditions of hydroponic plant growth as are known in the art. Medium samples are taken at several time points (4 h, 24 h and 48 h) and the number of CFU/ml is counted. Probiotic bacteria propagating in the hydroponic medium are selected.
- Selected bacteria are grown to form a cell culture and added to the medium of hydroponically grown plants (e.g. lettuce). After about three and/or five days, leaf samples are taken, grinded in a buffer, and the number of CFU/leaf weight is measured as described hereinabove.
- The above-described protocols are suitable for selecting and/or enriching for probiotic bacteria with endophytic growth capabilities using other plants with edible leaves, for example spinach.
- The capability of the selected bacteria colonies to enter and grow in the plant is validated by isolating the bacteria from newly developed leaves to which the bacteria were migrated; growing the selected bacteria in sterile cultures; and applying the resulted culture to new plants according to the first method applied (leaf infiltration, seed coating, or immersion). The procedure is repeated for 2-10 rounds. The results of an exemplary experiment, in which the bacteria were first applied by seed coating, are presented in Table 3 hereinbelow.
-
TABLE 3 Quantification and identification of probiotic strain isolated from leaves of lettuce developed from coated seeds No. of Bacteria amount in lettuce leaves (log CFU/g) Enrichment Cycles 1 2 3 4 5 6 7 8 9 10 Bacillus Subtilis 4.623 TNTC* 7.505 4.905 4.825 Enterococcus Faecalis TNTC 8.161 7.663 TNTC 7.297 TNTC 6.924 TNTC 7.723 7.053 Lactobacillus Paracasei 7.927 7.877 7.699 5.155 6.017 6.017 5.079 6.526 7.927 7.877 *TNTC—too numerous to count - Probiotic bacteria that acquired endophytic characteristics (i.e. being capable of surviving and multiplying in a plant tissue at significant concentrations) selected as described hereinabove are defined as colonized bacteria having endophytic characteristics. The endophytic characteristics of the selected bacteria was examined by separating bacteria present onto the leaves (epiphytic bacteria) and bacteria present within the leaf tissue (endophytic bacteria).
- Lettuce seeds were coated with probiotic bacteria (E. faecalis, L. Paracasei or B. subtilis) and Carboxymethyl cellulose (CMC) solution as described hereinabove. The coated seeds were germinated in aseptic system. After 12 days, leaf samples of plants grown from the coated seeds were collected. Samples were sonicated in 900 μl sterilized saline in sonication bath (ultrasonic Elmasonic S 10/H;
Frequency 50/60 H) for 7 min and then both saline (representing epiphytic bacteria) and crushed sonicated leaves (representing endophytic bacteria) were plated on supportive medium. In addition, leaves without sonication were sampled (sampling both epiphytic and endophytic bacteria). Data were subjected to one-way ANOVA, and pair-comparison of treatment means was achieved by Tukey's procedure at P<0.05, using a statistical software (JMP). As is shown inFIG. 1 , the bacteria partitioned between the outer part and the inner tissues of the leaves in comparable concentrations. It is to be noted that detachment of tightly surface-attached bacteria by sonication enabled improved growth of these bacteria on the supportive medium compared to the growth of bacteria of the control leaves which were not subjected to sonication. Sonication has been recently shown to be an acceptable method for removing surface-attached bacteria (Richter-Heitmann T et al., 2016. Frontiers inMicrobiology 7, Article 773, doi: 10.3389/fmicb.2016.00773; Qvit-Raz N et al. 2008. Genetics 178(3): 1615-1622. doi: 10.1534/genetics.107.082164; Beattie G A and Lindow S E. 1999. Phytopathology 89(5):353-9. doi: 10.1094/PHYTO.1999.89.5.353). - In order to ensure that bacteria acquired endophytic characteristics did not lose their probiotic characteristics, colonized bacteria isolate of E. Faecalis, L. Paracasei, and B. subtilis were examined. The examined bacteria were isolated from lettuce leaves of plants after seven cycles of seed coating (with culture each of the bacteria species)—plant growth—isolation of bacteria from the plant leaves, confirming the endophytic growth characteristics of the bacteria.
- The isolated bacteria were grown in solutions simulating gastric fluid (SGF, containing 2 grams of NaCl; 3.2 g pepsin (Sigma; and 80 mL of 1 M HCl; mixed together to make 1 L with distilled water). In one experiment, the effect of acidic pH (pH−2 and pH=4) was examined, using SGF containing pepsin. The experiment was conducted as follows:
- Original isolates of the above-described probiotic bacteria (i.e. isolates not subjected to growth cycles in plant tissues) were used as a control. Bacteria (test and control) were harvested after 18 h growth in BHI or MRS or NB (Nutrient broth, Millipore)—medium culture by centrifugation (5,000×g, 10 min, 4° C.) and washed twice with PBS (pH 7.2). 1 mL of the cell suspensions (free cells) was gently mixed with 10 mL of sterile simulated gastric juice and resuspended in 10 ml of SGF pre-warmed to 37° C. The cell suspensions were incubated for 120 min at 37° C. in aerobic condition under stirring (≈200 rpm). Samples were taken at 0, 30, 60, 120 min and plated on BHI\MRS\NB agar. Survival was examined by counting the number of CFUs, wherein the number of CFU at
time 0 taken as a control. - As is shown in
FIG. 2 , no significant differences could be observed in the survival rate of the bacteria acquired endophytic characteristics compared to the original probiotic isolates. - In another experiment, the effect of a solution simulating intestinal fluid (SIF) containing pancreatic enzymes was examined (SIF: 6.8 g of monobasic potassium phosphate, 1 g of Pancreatine (Sigma) and 77 ml of 0.2N NaOH mixed together to make 1 L with distilled water. pH of the solution was corrected to pH 6.8 by adding 0.2N NaOH). Probiotic bacteria as above (colonized bacteria that acquired endophytic characteristics and original isolates) were grown essentially as described above, resuspending the harvested cell in SIF. The cell cultures were incubated for 4 h at 37° C. in aerobic condition under stirring (≈200 rpm). Samples were taken at 0, 120, 240 min., plated on BHI\MRS\NB agar and survival rate was measured. Each assay was performed in triplicates. As for the solutions simulating gastric fluid, the colonized exogenic bacteria isolated showed similar survival rate is solution simulating intestinal fluid compared to the original isolates (
FIG. 3 ). These results clearly demonstrate that colonizing the probiotic bacteria in plant tissue conferring to the probiotic bacteria endophytic characteristics had no adverse effect of the bacteria essential probiotic characteristics of resistance to the harsh environment of the gastrointestinal tract. - Lettuce seeds were coated with carboxymethyl cellulose (CMC) containing E. Faecalis (originated from cycle 10). The coated seeds were germinated in aseptic system of Hoagland No. 2 basal salt mixture agar (pH 6.5). Leaves, originating from plants germinated from the coated seeds, were sampled 8, 13, 20 and 28 days after sowing (plantlets were immersed around day 4). The bacteria were extracted from each sample by crushing the leaves in Saline and plating it on supportive medium. Colonies that grew on the supportive medium were identified by sequencing of 16S rRNA gene. Data were subjected to one-way ANOVA, and pair-comparison of treatment means was achieved by Tukey's procedure at P<0.05, using a statistical software (JMP). No significant difference in the bacteria amounts was observed during 28 days of growth (
FIG. 4 ). - Enterococcus faecalis bacteria were collected from agar plate and blended with two different solutions: double distilled water (DDW) and 2% carboximetilcelulose (CMC). The final concentration of the E. faecalis bacteria was 106 CFU/ml. To form bacteria-CMC suspension, the solution was vigorously shaken until homogenous suspension was obtained
- Lettuce cut leaves were dipped in each of the two different bacterial solutions for 10 minutes. The coated leaves were kept in a sterile box in the refrigerator at 4° C.
- After 3, 7 and 14 days, the bacteria were extracted from each sample by crushing the leaves in DDW and directly plating the mixture using serial dilutions on supportive medium. Untreated leaves (leaves not subjected to bacterial solution) served as control, and no probiotic bacteria were found in these leaves in all experiments. The different colonies that grew in the medium were identified by sequencing of 16S rRNA gene. Each analysis was performed in ten repeats. Data were subjected to one-way ANOVA, and pair-comparison of treatment means was achieved by Tukey's procedure at P<0.05, using a statistical software (JMP).
FIG. 5 demonstrates that CMC protected the bacteria present in the leaves while not interfering with its growth, as significantly higher number of CFU was detected when the leaves were dipped in a solution comprising CMC. - Mice (male C57BL/
6JOLAHSD mice 8 weeks old) are fed for two consecutive days with three different diets: - Control group (1): diet containing regular mice food (5 mice);
- Control group (2): diet containing regular mice food mixed with regular lettuce (5 mice);
- Test group: diet containing regular mice food mixed with lettuce enriched with the probiotic bacteria Enterococcus faecalis according to the teachings of the present invention (5 mice).
- Each mouse from
control group 2 and the test group is fed with 1 g lettuce per day for two consecutive days. From the third day onwards, all groups are fed with regular mice food only. - Stool from all mice is collected every day at the beginning of the dark phase, and immediately snap-frozen and transferred for storage at −80° C. until further processing. DNA is isolated from stool samples, using Power Soil Kit (QIAGEN) and the presence of E. faecalis in the stool is determined by q-PCR analysis of E. faecalis 16S rRNA and EDA-2 gene (Peykov S Z et al. 2012. Mol Biol Rep 39, 7025-7030. DOI 10.1007/s11033-012-1533-z).
- Mice are sacrificed on the fourth day, and contents of several parts of the gastrointestinal tract, especially from the colon and cecum are collected. Presence of E. faecalis in the intestinal contents is determined by q-PCR analysis. The colon undergo fixation in order to detect putative probiotic survival by FISH methodology (Chassaing B et al., 2015. Nature. 519(7541), 92-6. doi: 10.1038/nature14232; Johansson M E et al., 2012. Methods Mol Biol. 842, 229-35. doi: 10.1007/978-1-61779-513-8_13).
- The effect of plant vegetative tissues enriched with probiotic endophytic bacteria according to the teachings of the invention on prevention and/or treatment of intestinal inflammation is examined with mouse model of IBD induced by dextran sodium sulfate (DSS). The preventive or treatment protocol is performed essentially as previously described (Avram-Hananel, L., et al., Dis. Colon Rectum 53, 1676-1686, 2010). Non-treated mice are used as negative control and mice treated with the same species of isolated microbiotic endophytic bacteria are used as a positive control.
- Enterococcus faecalis and optionally also of Lactobacillus paracasei, are grown on agar of a respective medium overnight at a temperature of 28° C. Bacteria colonies are then picked and re-suspended in DDW containing 2% CMC to reach turbidity (OD at 600 nm=0.15). Solution containing 107 cfu/ml is taken for application.
- Lettuce plants are used as an example of fresh leafy produce. Lettuce plants (n=50) are grown under field conditions as is known in the art. About 5 days before harvest, 30 plants are sprayed with the bacteria-CMC solution. 20 plants serve as a control.
- After 5 days, all plants are harvested, and the lettuce leaves are washed with sterile DDW. Samples are taken from each plant (100 g tissue per sample). From each group (treated and control plant), 20-25 random samples are taken directly after the wash with DDW; 5-10 random samples are sonicated to detach epiphytic bacteria as described hereinabove; and 5-10 additional random samples are surface sterilized by at least one method (with ethanol, hypochlorite sodium (NaOCl) or a combination thereof).
- All samples are then crushed in sterile DDW and plated on a respective medium. Number of CFU/g tissue is calculated. Number of CFU/g identified in the sonicated and/or surface sterilized samples indicate endophytic bacteria.
- The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/046,103 US11957721B2 (en) | 2018-04-11 | 2019-04-10 | Edible plant parts enriched with probiotic bacteria |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862655819P | 2018-04-11 | 2018-04-11 | |
US17/046,103 US11957721B2 (en) | 2018-04-11 | 2019-04-10 | Edible plant parts enriched with probiotic bacteria |
PCT/IL2019/050403 WO2019198079A1 (en) | 2018-04-11 | 2019-04-10 | Edible plant parts enriched with probiotic bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210030819A1 true US20210030819A1 (en) | 2021-02-04 |
US11957721B2 US11957721B2 (en) | 2024-04-16 |
Family
ID=66554453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/046,103 Active 2039-06-02 US11957721B2 (en) | 2018-04-11 | 2019-04-10 | Edible plant parts enriched with probiotic bacteria |
Country Status (4)
Country | Link |
---|---|
US (1) | US11957721B2 (en) |
EP (1) | EP3773646A1 (en) |
JP (1) | JP2021526385A (en) |
WO (1) | WO2019198079A1 (en) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025004A (en) | 1988-06-13 | 1991-06-18 | Eastman Kodak Company | Water-dispersible polymeric compositions |
US4960814A (en) | 1988-06-13 | 1990-10-02 | Eastman Kodak Company | Water-dispersible polymeric compositions |
JP3124670B2 (en) * | 1993-12-17 | 2001-01-15 | サンスター株式会社 | New food material obtained by fermenting green-yellow vegetables and method for producing the same |
JP2006034262A (en) * | 2004-07-30 | 2006-02-09 | Sunstar Inc | Food composition |
ITMI20041887A1 (en) * | 2004-10-05 | 2005-01-05 | Consiglio Nazionale Ricerche | PROCEDURE FOR PREPARING PRESERVES VEGETABLE FOOD CONTAINING PROBIOTIC MICRO-ORGANISMS |
JP2009100677A (en) | 2007-10-23 | 2009-05-14 | Daiwarandam Co Ltd | Fruit and vegetable, and method for cultivating the fruit and vegetable |
WO2012037237A1 (en) | 2010-09-15 | 2012-03-22 | Investigacion De Tecnologia Avanzada, S.A. De C.V. | Bacillus subtilis isolate from corn |
EP3502235A1 (en) | 2012-09-19 | 2019-06-26 | Bioconsortia, Inc. | Methods of screening for microorganisms that impart beneficial properties to plants |
KR101495309B1 (en) * | 2012-12-31 | 2015-02-26 | 대상에프앤에프 주식회사 | New lactic acid bacteria Lactobacillus plantarum DSR KF12 isolated from Gimchi and composition comprising the same |
MY180486A (en) * | 2014-06-05 | 2020-11-30 | Univ Malaysia Sabah | Method for the production of dried probiotic food |
JP6382027B2 (en) * | 2014-08-26 | 2018-08-29 | サンスター株式会社 | Oral composition containing bifidobacteria and cruciferous vegetables |
JP5958985B1 (en) | 2015-12-04 | 2016-08-02 | 上坂 喜美枝 | Lactic acid bacteria solution, fermented product production method, edible plant production method, lactic acid bacteria solution production method |
WO2018050739A1 (en) * | 2016-09-14 | 2018-03-22 | Fermentationexperts A/S | Kimchi based on a rape species |
JP6508637B2 (en) | 2017-07-28 | 2019-05-08 | 株式会社ナリヒラ | Cultivation method of vegetables with lactic acid bacteria |
CN110367487B (en) * | 2019-07-19 | 2022-09-02 | 河北科技大学 | Probiotic-enriched dried fruit and vegetable and preparation method thereof |
-
2019
- 2019-04-10 JP JP2021504601A patent/JP2021526385A/en active Pending
- 2019-04-10 EP EP19724630.9A patent/EP3773646A1/en active Pending
- 2019-04-10 WO PCT/IL2019/050403 patent/WO2019198079A1/en unknown
- 2019-04-10 US US17/046,103 patent/US11957721B2/en active Active
Non-Patent Citations (6)
Title |
---|
Bai, et al., "Coating selection for 'Delicious' and other apples", Postharvest Biology and Technology, Vol. 28, pages 381-390. (Year: 2003) * |
Betoret, et al. "Development of probiotic-enriched dried fruits by vacuum impregnation", Journal of Food Engineering, Vol. 56, pages 273-277. (Year: 2003) * |
Macey, Bobby. "Which Apple Is The Healthiest For You?", SelectHealth, https://selecthealth.org/blog/2016/07/healthiest-apple (Accessed: July 2022) (Year: 2016) * |
Rößle et al. "Development of potentially synbiotic fresh-cut apple slices", Journal of Functional Foods, Vol. 2, pages 245-254. (Year: 2010) * |
Rößle et al. "Evaluation of fresh-cut apple slices enriched with probiotic bacteria", Innovative Food Science and Emerging Technologies, Vol. 11, pages 203-209. (Year: 2010) * |
Trias et al., "Bioprotection of Golden Delicious apples and Iceberg lettuce against foodborne bacterial pathogens by lactic acid bacteria", International Journal of Food Microbiology, Vol. 123, pages 50-60. (Year: 2008) * |
Also Published As
Publication number | Publication date |
---|---|
JP2021526385A (en) | 2021-10-07 |
WO2019198079A1 (en) | 2019-10-17 |
EP3773646A1 (en) | 2021-02-17 |
US11957721B2 (en) | 2024-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180207165A1 (en) | Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract | |
JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
CN110964655B (en) | Bifidobacterium lactis BL-99 and application thereof | |
JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
JP5830084B2 (en) | Method of using Bacillus subtilis strains for the prevention and treatment of gastrointestinal conditions | |
CN100455203C (en) | A probiotic composition comprising at least two lactic acid bacterial strains which are able to colonise the gastrointestinal tracts in combination with having intestinal survival property, intestinal | |
JP2004534512A (en) | Bacterial strains, treated plant extracts, compositions containing them, methods for their preparation, and their therapeutic and industrial applications | |
Wang et al. | Assessment of probiotic properties of Lactobacillus plantarum ZLP001 isolated from gastrointestinal tract of weaning pigs | |
MX2013002839A (en) | Bacillus subtilis isolate from corn. | |
US20180187274A1 (en) | Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof | |
JPWO2008023580A1 (en) | Animal feed additive | |
Kumar et al. | Bifidobacteria for life betterment | |
US11957721B2 (en) | Edible plant parts enriched with probiotic bacteria | |
ES2965365T3 (en) | Bacterial strain and its use | |
Birmani et al. | Probiotic supplementation in poultry production as an alternative to antibiotic feed additive | |
JP7267536B2 (en) | Method for producing lactic acid-fermented carrot | |
O'Sullivan | Primary sources of probiotic cultures | |
CN1806676B (en) | Powder,Liquid,Paste or gas formal life-beneficial extended-spectrum nutrition products | |
Istiqomah et al. | Synergistic effect between Lactobacillus plantarum AKK30 and Saccharomyces cerevisiae B18 and the probiotic properties of microencapsulated cultures | |
Razafindralambo et al. | Applications and Action Mechanisms of Probiotic-Based Multi-Components | |
Haben Fesseha | Probiotics and Its Potential Role in Poultry Production: A | |
CN111972669A (en) | Probiotic powder for enhancing immunity and preparation method thereof | |
AU2011218616B2 (en) | Ostrich feed supplement | |
Keerthi et al. | Enzymes in Probiotics | |
Jantarathin | INCREASING VIABILITY OF PROBIOTIC BACTERIA CO-ENCAPSULATED WITH PREBIOTIC FOR DISEASE RESISTANCE IN WHITE SHRIMP Litopenaeus vannamei |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALMON, RONI;REEL/FRAME:058874/0706 Effective date: 20201228 Owner name: OFEK ESHKOLOT R&D LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IASUR KRUH, LILACH;NAAMA-AMAR, ALAA;REEL/FRAME:058874/0674 Effective date: 20201228 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHOSEYOV, ODED;BARUCH-SHARON, SIGAL;SCHWARTZ, BETTY;REEL/FRAME:060605/0119 Effective date: 20190501 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING TC RESP., ISSUE FEE NOT PAID |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
AS | Assignment |
Owner name: OFEK - ESHKOLOT RESEARCH AND DEVELOPMENT LTD., ISRAEL Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 58874 FRAME: 674. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:IASUR KRUH, LILACH;NAAMA-AMAR, ALAA;REEL/FRAME:066957/0787 Effective date: 20201228 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |